JP6431367B2 - PGC−1αを調節するペプチド - Google Patents
PGC−1αを調節するペプチド Download PDFInfo
- Publication number
- JP6431367B2 JP6431367B2 JP2014500420A JP2014500420A JP6431367B2 JP 6431367 B2 JP6431367 B2 JP 6431367B2 JP 2014500420 A JP2014500420 A JP 2014500420A JP 2014500420 A JP2014500420 A JP 2014500420A JP 6431367 B2 JP6431367 B2 JP 6431367B2
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- stereoisomers
- pharmaceutically acceptable
- cosmetically
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 166
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 45
- 101001123331 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Proteins 0.000 title claims description 36
- 102100028960 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Human genes 0.000 title claims description 31
- 239000000203 mixture Substances 0.000 claims description 147
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 140
- 239000000284 extract Substances 0.000 claims description 99
- 150000003839 salts Chemical class 0.000 claims description 88
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 82
- -1 lipospheres Substances 0.000 claims description 81
- 239000003795 chemical substances by application Substances 0.000 claims description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 58
- 239000002537 cosmetic Substances 0.000 claims description 50
- 210000003491 skin Anatomy 0.000 claims description 50
- 208000035475 disorder Diseases 0.000 claims description 41
- 201000010099 disease Diseases 0.000 claims description 40
- 238000003786 synthesis reaction Methods 0.000 claims description 37
- 210000001789 adipocyte Anatomy 0.000 claims description 36
- 230000015572 biosynthetic process Effects 0.000 claims description 36
- 210000000577 adipose tissue Anatomy 0.000 claims description 34
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 108010016731 PPAR gamma Proteins 0.000 claims description 27
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 26
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 26
- 206010000496 acne Diseases 0.000 claims description 25
- 235000001014 amino acid Nutrition 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 150000001413 amino acids Chemical class 0.000 claims description 24
- 201000004624 Dermatitis Diseases 0.000 claims description 23
- 206010007882 Cellulitis Diseases 0.000 claims description 21
- 208000001126 Keratosis Diseases 0.000 claims description 21
- 230000004069 differentiation Effects 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 21
- 239000003112 inhibitor Substances 0.000 claims description 20
- 235000018102 proteins Nutrition 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 18
- 230000032683 aging Effects 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 201000004681 Psoriasis Diseases 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 239000003921 oil Substances 0.000 claims description 15
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 15
- 229920000642 polymer Polymers 0.000 claims description 15
- 201000010153 skin papilloma Diseases 0.000 claims description 15
- 210000004027 cell Anatomy 0.000 claims description 14
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 208000011580 syndromic disease Diseases 0.000 claims description 14
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 13
- 150000002632 lipids Chemical class 0.000 claims description 13
- 235000019198 oils Nutrition 0.000 claims description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 12
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 11
- 230000033228 biological regulation Effects 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 11
- 239000000021 stimulant Substances 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 206010011985 Decubitus ulcer Diseases 0.000 claims description 10
- 208000008589 Obesity Diseases 0.000 claims description 10
- 206010051246 Photodermatosis Diseases 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 10
- 230000003796 beauty Effects 0.000 claims description 10
- 230000007423 decrease Effects 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 206010025135 lupus erythematosus Diseases 0.000 claims description 10
- 239000004530 micro-emulsion Substances 0.000 claims description 10
- 235000020824 obesity Nutrition 0.000 claims description 10
- 230000008845 photoaging Effects 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 206010039710 Scleroderma Diseases 0.000 claims description 9
- 239000000839 emulsion Substances 0.000 claims description 9
- 239000003205 fragrance Substances 0.000 claims description 9
- 230000001965 increasing effect Effects 0.000 claims description 9
- 230000035755 proliferation Effects 0.000 claims description 9
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 9
- 208000000044 Amnesia Diseases 0.000 claims description 8
- 208000014094 Dystonic disease Diseases 0.000 claims description 8
- 208000018737 Parkinson disease Diseases 0.000 claims description 8
- 208000009621 actinic keratosis Diseases 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 208000010118 dystonia Diseases 0.000 claims description 8
- 210000002950 fibroblast Anatomy 0.000 claims description 8
- 239000000693 micelle Substances 0.000 claims description 8
- 201000004700 rosacea Diseases 0.000 claims description 8
- 238000013268 sustained release Methods 0.000 claims description 8
- 239000012730 sustained-release form Substances 0.000 claims description 8
- 206010024604 Lipoatrophy Diseases 0.000 claims description 7
- 239000004744 fabric Substances 0.000 claims description 7
- 210000002510 keratinocyte Anatomy 0.000 claims description 7
- 208000006132 lipodystrophy Diseases 0.000 claims description 7
- 208000030159 metabolic disease Diseases 0.000 claims description 7
- 208000005264 motor neuron disease Diseases 0.000 claims description 7
- 239000004745 nonwoven fabric Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 7
- 208000035484 Cellulite Diseases 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 6
- 108020004414 DNA Proteins 0.000 claims description 6
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims description 6
- 208000026139 Memory disease Diseases 0.000 claims description 6
- 206010049752 Peau d'orange Diseases 0.000 claims description 6
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 206010015037 epilepsy Diseases 0.000 claims description 6
- 239000000835 fiber Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 230000035876 healing Effects 0.000 claims description 6
- 239000002088 nanocapsule Substances 0.000 claims description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 206010003591 Ataxia Diseases 0.000 claims description 5
- 229920000858 Cyclodextrin Polymers 0.000 claims description 5
- 208000002506 Darier Disease Diseases 0.000 claims description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 5
- 206010023369 Keratosis follicular Diseases 0.000 claims description 5
- 239000005913 Maltodextrin Substances 0.000 claims description 5
- 229920002774 Maltodextrin Polymers 0.000 claims description 5
- 206010028703 Nail psoriasis Diseases 0.000 claims description 5
- 206010068322 Oral papilloma Diseases 0.000 claims description 5
- 241001303601 Rosacea Species 0.000 claims description 5
- 206010039792 Seborrhoea Diseases 0.000 claims description 5
- 206010047642 Vitiligo Diseases 0.000 claims description 5
- 208000000260 Warts Diseases 0.000 claims description 5
- 208000004631 alopecia areata Diseases 0.000 claims description 5
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 230000001934 delay Effects 0.000 claims description 5
- 230000003325 follicular Effects 0.000 claims description 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 5
- 206010021198 ichthyosis Diseases 0.000 claims description 5
- 210000001117 keloid Anatomy 0.000 claims description 5
- 201000004607 keratosis follicularis Diseases 0.000 claims description 5
- 208000002741 leukoplakia Diseases 0.000 claims description 5
- 230000037356 lipid metabolism Effects 0.000 claims description 5
- 239000002502 liposome Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 229940035034 maltodextrin Drugs 0.000 claims description 5
- 206010065988 nodular fasciitis Diseases 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000000419 plant extract Substances 0.000 claims description 5
- 201000006081 pseudosarcomatous fibromatosis Diseases 0.000 claims description 5
- 230000001185 psoriatic effect Effects 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 208000031091 Amnestic disease Diseases 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 208000001840 Dandruff Diseases 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 102000016942 Elastin Human genes 0.000 claims description 4
- 108010014258 Elastin Proteins 0.000 claims description 4
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 4
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 4
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 208000002260 Keloid Diseases 0.000 claims description 4
- 206010023330 Keloid scar Diseases 0.000 claims description 4
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 4
- 201000002832 Lewy body dementia Diseases 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 208000026072 Motor neurone disease Diseases 0.000 claims description 4
- 208000016285 Movement disease Diseases 0.000 claims description 4
- 206010062575 Muscle contracture Diseases 0.000 claims description 4
- 208000007256 Nevus Diseases 0.000 claims description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- 206010034010 Parkinsonism Diseases 0.000 claims description 4
- 206010034277 Pemphigoid Diseases 0.000 claims description 4
- 206010034912 Phobia Diseases 0.000 claims description 4
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 4
- 208000012641 Pigmentation disease Diseases 0.000 claims description 4
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 4
- 208000015390 Sebaceous gland disease Diseases 0.000 claims description 4
- 206010039966 Senile dementia Diseases 0.000 claims description 4
- 206010040867 Skin hypertrophy Diseases 0.000 claims description 4
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 4
- 208000016620 Tourette disease Diseases 0.000 claims description 4
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims description 4
- 208000018839 Wilson disease Diseases 0.000 claims description 4
- 230000002293 adipogenic effect Effects 0.000 claims description 4
- 230000006986 amnesia Effects 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 239000003429 antifungal agent Substances 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 4
- 230000037424 autonomic function Effects 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 230000015556 catabolic process Effects 0.000 claims description 4
- 208000006111 contracture Diseases 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 238000006731 degradation reaction Methods 0.000 claims description 4
- 230000018044 dehydration Effects 0.000 claims description 4
- 238000006297 dehydration reaction Methods 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 229920002549 elastin Polymers 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 230000004110 gluconeogenesis Effects 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 230000003779 hair growth Effects 0.000 claims description 4
- 210000003128 head Anatomy 0.000 claims description 4
- 210000004276 hyalin Anatomy 0.000 claims description 4
- 208000013403 hyperactivity Diseases 0.000 claims description 4
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 239000003410 keratolytic agent Substances 0.000 claims description 4
- 230000028252 learning or memory Effects 0.000 claims description 4
- 201000011486 lichen planus Diseases 0.000 claims description 4
- 230000002366 lipolytic effect Effects 0.000 claims description 4
- 208000024714 major depressive disease Diseases 0.000 claims description 4
- 230000006984 memory degeneration Effects 0.000 claims description 4
- 208000023060 memory loss Diseases 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 206010028417 myasthenia gravis Diseases 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 208000019899 phobic disease Diseases 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 239000002516 radical scavenger Substances 0.000 claims description 4
- 230000036573 scar formation Effects 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 230000037380 skin damage Effects 0.000 claims description 4
- 206010040882 skin lesion Diseases 0.000 claims description 4
- 231100000444 skin lesion Toxicity 0.000 claims description 4
- 208000019116 sleep disease Diseases 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 230000000638 stimulation Effects 0.000 claims description 4
- 210000000434 stratum corneum Anatomy 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
- 208000027534 Emotional disease Diseases 0.000 claims description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 3
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 3
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 3
- 206010026749 Mania Diseases 0.000 claims description 3
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 3
- 102000000536 PPAR gamma Human genes 0.000 claims description 3
- 206010040925 Skin striae Diseases 0.000 claims description 3
- 208000031439 Striae Distensae Diseases 0.000 claims description 3
- 230000005856 abnormality Effects 0.000 claims description 3
- 230000002776 aggregation Effects 0.000 claims description 3
- 238000004220 aggregation Methods 0.000 claims description 3
- 235000008206 alpha-amino acids Nutrition 0.000 claims description 3
- 230000001153 anti-wrinkle effect Effects 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 3
- 229940106189 ceramide Drugs 0.000 claims description 3
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 3
- 239000003086 colorant Substances 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 claims description 3
- 230000004151 fermentation Effects 0.000 claims description 3
- 239000010408 film Substances 0.000 claims description 3
- 208000037824 growth disorder Diseases 0.000 claims description 3
- 201000000079 gynecomastia Diseases 0.000 claims description 3
- 208000014188 hereditary optic neuropathy Diseases 0.000 claims description 3
- 208000008675 hereditary spastic paraplegia Diseases 0.000 claims description 3
- 230000004130 lipolysis Effects 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000008774 maternal effect Effects 0.000 claims description 3
- 210000002752 melanocyte Anatomy 0.000 claims description 3
- 239000003094 microcapsule Substances 0.000 claims description 3
- 230000004089 microcirculation Effects 0.000 claims description 3
- 239000007908 nanoemulsion Substances 0.000 claims description 3
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims description 3
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 3
- 208000019906 panic disease Diseases 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 239000003223 protective agent Substances 0.000 claims description 3
- 230000000698 schizophrenic effect Effects 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 230000008961 swelling Effects 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- 102000008490 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Human genes 0.000 claims description 2
- 108010020504 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Proteins 0.000 claims description 2
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 claims description 2
- 239000002677 5-alpha reductase inhibitor Substances 0.000 claims description 2
- 235000007173 Abies balsamea Nutrition 0.000 claims description 2
- 102000012440 Acetylcholinesterase Human genes 0.000 claims description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 claims description 2
- 102000010637 Aquaporins Human genes 0.000 claims description 2
- 108010063290 Aquaporins Proteins 0.000 claims description 2
- 239000004857 Balsam Substances 0.000 claims description 2
- 241000195940 Bryophyta Species 0.000 claims description 2
- 101710163595 Chaperone protein DnaK Proteins 0.000 claims description 2
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 2
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- 206010011732 Cyst Diseases 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 230000033616 DNA repair Effects 0.000 claims description 2
- 102000004237 Decorin Human genes 0.000 claims description 2
- 108090000738 Decorin Proteins 0.000 claims description 2
- 102000000541 Defensins Human genes 0.000 claims description 2
- 108010002069 Defensins Proteins 0.000 claims description 2
- 102000016359 Fibronectins Human genes 0.000 claims description 2
- 108010067306 Fibronectins Proteins 0.000 claims description 2
- 229940123457 Free radical scavenger Drugs 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims description 2
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 claims description 2
- 102000004157 Hydrolases Human genes 0.000 claims description 2
- 108090000604 Hydrolases Proteins 0.000 claims description 2
- 244000018716 Impatiens biflora Species 0.000 claims description 2
- 239000004909 Moisturizer Substances 0.000 claims description 2
- 108010006519 Molecular Chaperones Proteins 0.000 claims description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 2
- 229940078467 Prolyl hydroxylase inhibitor Drugs 0.000 claims description 2
- 102000011990 Sirtuin Human genes 0.000 claims description 2
- 108050002485 Sirtuin Proteins 0.000 claims description 2
- 102000034337 acetylcholine receptors Human genes 0.000 claims description 2
- 229940022698 acetylcholinesterase Drugs 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 238000003915 air pollution Methods 0.000 claims description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 2
- 150000001371 alpha-amino acids Chemical class 0.000 claims description 2
- 229940035674 anesthetics Drugs 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000003712 anti-aging effect Effects 0.000 claims description 2
- 230000002682 anti-psoriatic effect Effects 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 239000003096 antiparasitic agent Substances 0.000 claims description 2
- 229940125687 antiparasitic agent Drugs 0.000 claims description 2
- 239000003908 antipruritic agent Substances 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 239000002249 anxiolytic agent Substances 0.000 claims description 2
- 239000000022 bacteriostatic agent Substances 0.000 claims description 2
- 239000000440 bentonite Substances 0.000 claims description 2
- 229910000278 bentonite Inorganic materials 0.000 claims description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 2
- 150000001277 beta hydroxy acids Chemical class 0.000 claims description 2
- 229920001222 biopolymer Polymers 0.000 claims description 2
- 239000007844 bleaching agent Substances 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 230000019522 cellular metabolic process Effects 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 229940112822 chewing gum Drugs 0.000 claims description 2
- 235000015218 chewing gum Nutrition 0.000 claims description 2
- 239000000812 cholinergic antagonist Substances 0.000 claims description 2
- 230000004087 circulation Effects 0.000 claims description 2
- 230000011382 collagen catabolic process Effects 0.000 claims description 2
- 238000004040 coloring Methods 0.000 claims description 2
- 229940097362 cyclodextrins Drugs 0.000 claims description 2
- 208000031513 cyst Diseases 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- 239000003602 elastase inhibitor Substances 0.000 claims description 2
- 239000003974 emollient agent Substances 0.000 claims description 2
- 230000003176 fibrotic effect Effects 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000003193 general anesthetic agent Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000003966 growth inhibitor Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 239000000411 inducer Substances 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 229940040145 liniment Drugs 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 230000008099 melanin synthesis Effects 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- 235000011929 mousse Nutrition 0.000 claims description 2
- 230000004118 muscle contraction Effects 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000002077 nanosphere Substances 0.000 claims description 2
- 239000002353 niosome Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 229920000620 organic polymer Polymers 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 230000003711 photoprotective effect Effects 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 230000019612 pigmentation Effects 0.000 claims description 2
- 230000001012 protector Effects 0.000 claims description 2
- 238000007634 remodeling Methods 0.000 claims description 2
- 210000002374 sebum Anatomy 0.000 claims description 2
- 229940125723 sedative agent Drugs 0.000 claims description 2
- 239000000932 sedative agent Substances 0.000 claims description 2
- 230000037307 sensitive skin Effects 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 208000020685 sleep-wake disease Diseases 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000002047 solid lipid nanoparticle Substances 0.000 claims description 2
- 230000000475 sunscreen effect Effects 0.000 claims description 2
- 239000000516 sunscreening agent Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 230000008728 vascular permeability Effects 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 239000000341 volatile oil Substances 0.000 claims description 2
- 230000002087 whitening effect Effects 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 5
- 229940122858 Elastase inhibitor Drugs 0.000 claims 1
- 101710108470 Hyalin Proteins 0.000 claims 1
- 206010060708 Induration Diseases 0.000 claims 1
- 241001272720 Medialuna californiensis Species 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims 1
- 229940122055 Serine protease inhibitor Drugs 0.000 claims 1
- 101710102218 Serine protease inhibitor Proteins 0.000 claims 1
- 239000004902 Softening Agent Substances 0.000 claims 1
- 206010048327 Supranuclear palsy Diseases 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 230000001166 anti-perspirative effect Effects 0.000 claims 1
- 230000001139 anti-pruritic effect Effects 0.000 claims 1
- 239000003213 antiperspirant Substances 0.000 claims 1
- 239000003241 dermatological agent Substances 0.000 claims 1
- 229940000033 dermatological agent Drugs 0.000 claims 1
- 239000000645 desinfectant Substances 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 230000003161 proteinsynthetic effect Effects 0.000 claims 1
- 239000003001 serine protease inhibitor Substances 0.000 claims 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 190
- 239000012071 phase Substances 0.000 description 56
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 53
- 238000000034 method Methods 0.000 description 45
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 32
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
- 239000011347 resin Substances 0.000 description 28
- 229920005989 resin Polymers 0.000 description 28
- 235000011187 glycerol Nutrition 0.000 description 26
- 229960005150 glycerol Drugs 0.000 description 26
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- 229940024606 amino acid Drugs 0.000 description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 23
- 125000006239 protecting group Chemical group 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 21
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 20
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 206010033675 panniculitis Diseases 0.000 description 18
- 238000003756 stirring Methods 0.000 description 18
- 210000000481 breast Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 210000004003 subcutaneous fat Anatomy 0.000 description 17
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 16
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 16
- 229960001948 caffeine Drugs 0.000 description 16
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 16
- 235000010469 Glycine max Nutrition 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 15
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 15
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 14
- 239000000787 lecithin Substances 0.000 description 14
- 229940067606 lecithin Drugs 0.000 description 14
- 235000010445 lecithin Nutrition 0.000 description 14
- 244000068988 Glycine max Species 0.000 description 13
- 125000003118 aryl group Chemical group 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 229960005323 phenoxyethanol Drugs 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 11
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 11
- 241000209140 Triticum Species 0.000 description 11
- 235000021307 Triticum Nutrition 0.000 description 11
- 229960004203 carnitine Drugs 0.000 description 11
- 125000000623 heterocyclic group Chemical group 0.000 description 11
- 210000000689 upper leg Anatomy 0.000 description 11
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 10
- 102000040945 Transcription factor Human genes 0.000 description 10
- 108091023040 Transcription factor Proteins 0.000 description 10
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 10
- 235000005340 Asparagus officinalis Nutrition 0.000 description 9
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 9
- 244000193174 agave Species 0.000 description 9
- 210000001217 buttock Anatomy 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- UGNIYGNGCNXHTR-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UGNIYGNGCNXHTR-SFHVURJKSA-N 0.000 description 8
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 8
- 229940043375 1,5-pentanediol Drugs 0.000 description 8
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 229910019142 PO4 Inorganic materials 0.000 description 8
- 229920002125 Sokalan® Polymers 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 125000003710 aryl alkyl group Chemical group 0.000 description 8
- 238000010352 biotechnological method Methods 0.000 description 8
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 239000003925 fat Substances 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 8
- 239000001341 hydroxy propyl starch Substances 0.000 description 8
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 8
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 8
- 239000010452 phosphate Substances 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 8
- 230000000699 topical effect Effects 0.000 description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 7
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 description 7
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 7
- 206010040954 Skin wrinkling Diseases 0.000 description 7
- 108010073771 Soybean Proteins Proteins 0.000 description 7
- 230000011759 adipose tissue development Effects 0.000 description 7
- 229960001631 carbomer Drugs 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- 210000000744 eyelid Anatomy 0.000 description 7
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 7
- 239000007790 solid phase Substances 0.000 description 7
- 229940001941 soy protein Drugs 0.000 description 7
- 230000037303 wrinkles Effects 0.000 description 7
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 description 6
- 235000021508 Coleus Nutrition 0.000 description 6
- 244000061182 Coleus blumei Species 0.000 description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N THREONINE Chemical compound CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 6
- 125000001931 aliphatic group Chemical group 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 235000019445 benzyl alcohol Nutrition 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 229940093441 palmitoyl oligopeptide Drugs 0.000 description 6
- 238000010647 peptide synthesis reaction Methods 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 6
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- GKPMARPRXONRJX-BWJWTDLKSA-N (3s)-4-[[(2s,3s)-1-[[(2s)-1-amino-5-(carbamoylamino)-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-[[(2s)-2,6-diaminohexanoyl]amino]-4-oxobutanoic acid Chemical compound NC(=O)NCCC[C@@H](C(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCCCN GKPMARPRXONRJX-BWJWTDLKSA-N 0.000 description 5
- JMYNPQVCVQVODQ-OWOJBTEDSA-N 1,3-dichloro-5-[(e)-2-(4-chlorophenyl)ethenyl]benzene Chemical compound C1=CC(Cl)=CC=C1\C=C\C1=CC(Cl)=CC(Cl)=C1 JMYNPQVCVQVODQ-OWOJBTEDSA-N 0.000 description 5
- 244000144725 Amygdalus communis Species 0.000 description 5
- 235000011437 Amygdalus communis Nutrition 0.000 description 5
- 235000005320 Coleus barbatus Nutrition 0.000 description 5
- 101001134680 Drosophila melanogaster POU domain protein 2, isoform A Proteins 0.000 description 5
- 101001134679 Drosophila melanogaster POU domain protein 2, isoform B Proteins 0.000 description 5
- 101001134678 Drosophila virilis POU domain protein 2 Proteins 0.000 description 5
- 240000008669 Hedera helix Species 0.000 description 5
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 5
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 5
- 241000131459 Plectranthus barbatus Species 0.000 description 5
- 241000519590 Pseudoalteromonas Species 0.000 description 5
- RTMWIZOXNKJHRE-UHFFFAOYSA-N Tigogenin Natural products CC1COC2CC(C)(OC12)C3CCC4C5CCC6CC(O)CCC6(C)C5CCC34C RTMWIZOXNKJHRE-UHFFFAOYSA-N 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 229960003237 betaine Drugs 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 229960002173 citrulline Drugs 0.000 description 5
- 235000013477 citrulline Nutrition 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 238000007429 general method Methods 0.000 description 5
- 230000006372 lipid accumulation Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229920001285 xanthan gum Polymers 0.000 description 5
- 239000000230 xanthan gum Substances 0.000 description 5
- 235000010493 xanthan gum Nutrition 0.000 description 5
- 229940082509 xanthan gum Drugs 0.000 description 5
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 4
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 4
- 235000000008 Alchemilla vulgaris Nutrition 0.000 description 4
- 244000144927 Aloe barbadensis Species 0.000 description 4
- 235000002961 Aloe barbadensis Nutrition 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 244000183685 Citrus aurantium Species 0.000 description 4
- 235000007716 Citrus aurantium Nutrition 0.000 description 4
- 235000013162 Cocos nucifera Nutrition 0.000 description 4
- 244000060011 Cocos nucifera Species 0.000 description 4
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 4
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
- 244000194101 Ginkgo biloba Species 0.000 description 4
- 235000008100 Ginkgo biloba Nutrition 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- 235000021314 Palmitic acid Nutrition 0.000 description 4
- 240000003444 Paullinia cupana Species 0.000 description 4
- 235000000556 Paullinia cupana Nutrition 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 235000003142 Sambucus nigra Nutrition 0.000 description 4
- 240000006028 Sambucus nigra Species 0.000 description 4
- GMBQZIIUCVWOCD-WWASVFFGSA-N Sarsapogenine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 GMBQZIIUCVWOCD-WWASVFFGSA-N 0.000 description 4
- 229920002385 Sodium hyaluronate Polymers 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- 235000012044 Yucca brevifolia Nutrition 0.000 description 4
- 244000149006 Yucca filamentosa Species 0.000 description 4
- 210000003486 adipose tissue brown Anatomy 0.000 description 4
- 210000000593 adipose tissue white Anatomy 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 235000020224 almond Nutrition 0.000 description 4
- 235000011399 aloe vera Nutrition 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 229960000541 cetyl alcohol Drugs 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000003081 coactivator Effects 0.000 description 4
- 229940086555 cyclomethicone Drugs 0.000 description 4
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229940008099 dimethicone Drugs 0.000 description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 235000008995 european elder Nutrition 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 4
- 229960003646 lysine Drugs 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- RMGVATURDVPNOZ-UHFFFAOYSA-M potassium;hexadecyl hydrogen phosphate Chemical compound [K+].CCCCCCCCCCCCCCCCOP(O)([O-])=O RMGVATURDVPNOZ-UHFFFAOYSA-M 0.000 description 4
- 210000000229 preadipocyte Anatomy 0.000 description 4
- 238000007665 sagging Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 229940010747 sodium hyaluronate Drugs 0.000 description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 description 4
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 description 3
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical group CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 description 3
- UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 3
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 3
- BSXPDVKSFWQFRT-UHFFFAOYSA-N 1-hydroxytriazolo[4,5-b]pyridine Chemical compound C1=CC=C2N(O)N=NC2=N1 BSXPDVKSFWQFRT-UHFFFAOYSA-N 0.000 description 3
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 description 3
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 3
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 125000003974 3-carbamimidamidopropyl group Chemical group C(N)(=N)NCCC* 0.000 description 3
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 3
- HISMSXHVLNAPEQ-UHFFFAOYSA-N 5-[4-(aminomethyl)-3,5-dimethoxyphenoxy]pentanoic acid Chemical compound COC1=CC(OCCCCC(O)=O)=CC(OC)=C1CN HISMSXHVLNAPEQ-UHFFFAOYSA-N 0.000 description 3
- 240000004507 Abelmoschus esculentus Species 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 3
- 241000202726 Bupleurum Species 0.000 description 3
- 240000006162 Chenopodium quinoa Species 0.000 description 3
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 3
- 235000016646 Citrus taiwanica Nutrition 0.000 description 3
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 3
- 241000195493 Cryptophyta Species 0.000 description 3
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 description 3
- 244000061408 Eugenia caryophyllata Species 0.000 description 3
- 239000001653 FEMA 3120 Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 244000014603 Kigelia pinnata Species 0.000 description 3
- 235000002329 Kigelia pinnata Nutrition 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 241001466453 Laminaria Species 0.000 description 3
- 235000010649 Lupinus albus Nutrition 0.000 description 3
- 240000000894 Lupinus albus Species 0.000 description 3
- 235000017011 Mandorlo dulce Nutrition 0.000 description 3
- 244000076313 Mandorlo dulce Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- 244000061176 Nicotiana tabacum Species 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 241000912433 Paulinia Species 0.000 description 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 244000179560 Prunella vulgaris Species 0.000 description 3
- 206010040829 Skin discolouration Diseases 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 3
- 240000001519 Verbena officinalis Species 0.000 description 3
- 235000004552 Yucca aloifolia Nutrition 0.000 description 3
- 235000017049 Yucca glauca Nutrition 0.000 description 3
- 125000002015 acyclic group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 229960003121 arginine Drugs 0.000 description 3
- 229940009098 aspartate Drugs 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 235000011472 cat’s claw Nutrition 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 3
- 239000005516 coenzyme A Substances 0.000 description 3
- 229940093530 coenzyme a Drugs 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 3
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 description 3
- 208000024732 dysthymic disease Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000002837 heart atrium Anatomy 0.000 description 3
- 102000048781 human PPARGC1A Human genes 0.000 description 3
- AIPVRBGBHQDAPX-UHFFFAOYSA-N hydroxy(methyl)silane Chemical compound C[SiH2]O AIPVRBGBHQDAPX-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000003780 keratinization Effects 0.000 description 3
- 201000010901 lateral sclerosis Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229940068977 polysorbate 20 Drugs 0.000 description 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 229960001295 tocopherol Drugs 0.000 description 3
- 235000010384 tocopherol Nutrition 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 3
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- GMBQZIIUCVWOCD-UQHLGXRBSA-N (25R)-5beta-spirostan-3beta-ol Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 GMBQZIIUCVWOCD-UQHLGXRBSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- KQEQPUBSXXOUGC-MLCQCVOFSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-1-acetylpyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(C)=O)C(O)=O KQEQPUBSXXOUGC-MLCQCVOFSA-N 0.000 description 2
- OGNHOGPWQTWKGQ-VGWMRTNUSA-N (2S)-5-amino-2-[[(2S)-1-[2-[[(2S)-5-amino-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 OGNHOGPWQTWKGQ-VGWMRTNUSA-N 0.000 description 2
- GFEYWOGCSROPRT-OBXVVNIGSA-N (2s)-1-[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound C([C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 GFEYWOGCSROPRT-OBXVVNIGSA-N 0.000 description 2
- YXIBXUGCDCJBPD-JYJNAYRXSA-N (2s)-2,6-diamino-n-[2-[[(2s)-1-[[(2s)-1,6-diamino-1-oxohexan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]hexanamide Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(N)=O)CC1=CN=CN1 YXIBXUGCDCJBPD-JYJNAYRXSA-N 0.000 description 2
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 2
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 2
- ROTFCACGLKOUGI-JYJNAYRXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-(3-acetamidopropanoylamino)-3-(1h-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical group C([C@H](NC(=O)CCNC(=O)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 ROTFCACGLKOUGI-JYJNAYRXSA-N 0.000 description 2
- HKKVMNZTZSUQBC-KRCBVYEFSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-2-phenylacetyl]amino]-2-phenylacetic acid Chemical compound C1([C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C=2C=CC=CC=2)=CC=CC=C1 HKKVMNZTZSUQBC-KRCBVYEFSA-N 0.000 description 2
- OFGVZFQUFJYSGS-CPDXTSBQSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s,3s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O OFGVZFQUFJYSGS-CPDXTSBQSA-N 0.000 description 2
- ZHUJMSMQIPIPTF-JMBSJVKXSA-N (2s)-2-[[(2s)-2-[[2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ZHUJMSMQIPIPTF-JMBSJVKXSA-N 0.000 description 2
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 2
- LODWEXDBRZBADB-XEVVZDEMSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O LODWEXDBRZBADB-XEVVZDEMSA-N 0.000 description 2
- BVYVWYKOCOGULA-JBUMCTQMSA-N (2s,3r)-2-[[(2s)-4-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]butanoyl]amino]-3-hydroxybutanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BVYVWYKOCOGULA-JBUMCTQMSA-N 0.000 description 2
- QXVFEIPAZSXRGM-DJJJIMSYSA-N (2s,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@@H](C)CC)C(O)=O)C3=CC=CC=C3C2=C1 QXVFEIPAZSXRGM-DJJJIMSYSA-N 0.000 description 2
- QZLXCFQVOCEKSX-NOCHOARKSA-N (2s,4r)-1-hexadecanoyl-4-hexadecanoyloxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H]1C[C@@H](C(O)=O)N(C(=O)CCCCCCCCCCCCCCC)C1 QZLXCFQVOCEKSX-NOCHOARKSA-N 0.000 description 2
- ITIMHIATVYROGF-XWUOBKMESA-N (3S)-3-[[(2S)-2-acetamido-6-aminohexanoyl]amino]-4-[[(2S)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC(C)[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O ITIMHIATVYROGF-XWUOBKMESA-N 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 2
- QNZANUZIBYJBIN-XSWJXKHESA-N (3s)-3-[[(2s)-2-acetamido-5-amino-5-oxopentanoyl]amino]-4-[[(2s)-1-[[(1s)-1-carboxy-2-(1h-imidazol-5-yl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound NC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 QNZANUZIBYJBIN-XSWJXKHESA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 2
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 2
- KFLKTDAONDZLAN-UHFFFAOYSA-N 2-(n-phenylanilino)acetic acid Chemical compound C=1C=CC=CC=1N(CC(=O)O)C1=CC=CC=C1 KFLKTDAONDZLAN-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- AHJXIGQHVVYEGR-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;hydron;iodide Chemical compound I.OCCN(CCO)CCO AHJXIGQHVVYEGR-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- SABOFQQPIQQDHH-UHFFFAOYSA-N 3-[2-(2-fluorophenyl)pyrazol-3-yl]-1-[3-(trifluoromethyl)phenyl]pyridazin-4-one Chemical compound FC1=CC=CC=C1N1C(C=2C(C=CN(N=2)C=2C=C(C=CC=2)C(F)(F)F)=O)=CC=N1 SABOFQQPIQQDHH-UHFFFAOYSA-N 0.000 description 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
- JXPHIHWXMBYJAU-UHFFFAOYSA-N 7-methoxy-2,2-dimethyl-3,4-dihydrochromen-6-ol Chemical compound O1C(C)(C)CCC2=C1C=C(OC)C(O)=C2 JXPHIHWXMBYJAU-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 235000003934 Abelmoschus esculentus Nutrition 0.000 description 2
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 2
- 244000198134 Agave sisalana Species 0.000 description 2
- 235000011468 Albizia julibrissin Nutrition 0.000 description 2
- 241001092085 Alchemilla Species 0.000 description 2
- 244000082872 Alchemilla vulgaris Species 0.000 description 2
- 244000125300 Argania sideroxylon Species 0.000 description 2
- 241000086254 Arnica montana Species 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- NXTGWOGJZSSREB-HJXLNUONSA-N C[SiH2]O.O[C@H]1CN[C@H](C(O)=O)C1 Chemical compound C[SiH2]O.O[C@H]1CN[C@H](C(O)=O)C1 NXTGWOGJZSSREB-HJXLNUONSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 2
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 2
- 108010087806 Carnosine Proteins 0.000 description 2
- 235000004032 Centella asiatica Nutrition 0.000 description 2
- 244000146462 Centella asiatica Species 0.000 description 2
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 241000206575 Chondrus crispus Species 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 240000005250 Chrysanthemum indicum Species 0.000 description 2
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 240000007154 Coffea arabica Species 0.000 description 2
- 235000006965 Commiphora myrrha Nutrition 0.000 description 2
- 240000007311 Commiphora myrrha Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N DL-isoserine Natural products NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 description 2
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 240000008620 Fagopyrum esculentum Species 0.000 description 2
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 2
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 2
- 235000003222 Helianthus annuus Nutrition 0.000 description 2
- 244000020551 Helianthus annuus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 235000008694 Humulus lupulus Nutrition 0.000 description 2
- 244000025221 Humulus lupulus Species 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 235000017309 Hypericum perforatum Nutrition 0.000 description 2
- 244000141009 Hypericum perforatum Species 0.000 description 2
- 235000003368 Ilex paraguariensis Nutrition 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 208000006136 Leigh Disease Diseases 0.000 description 2
- 208000017507 Leigh syndrome Diseases 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 240000005852 Mimosa quadrivalvis Species 0.000 description 2
- NGYZAEAXQQNUBZ-FPOVZHCZSA-N N-Palmitoyl isoleucine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)[C@@H](C)CC NGYZAEAXQQNUBZ-FPOVZHCZSA-N 0.000 description 2
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 235000004496 Oenothera biennis Nutrition 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- 235000015933 Peumus boldus Nutrition 0.000 description 2
- 244000021273 Peumus boldus Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 108010047657 Phe-Val-Ala-Pro-Phe-Pro Proteins 0.000 description 2
- 244000203593 Piper nigrum Species 0.000 description 2
- 235000008184 Piper nigrum Nutrition 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 235000011449 Rosa Nutrition 0.000 description 2
- 235000000539 Rosa canina Nutrition 0.000 description 2
- 240000008530 Rosa canina Species 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 241000605385 Ruscus Species 0.000 description 2
- 235000003500 Ruscus aculeatus Nutrition 0.000 description 2
- 240000000353 Ruscus aculeatus Species 0.000 description 2
- 206010039796 Seborrhoeic keratosis Diseases 0.000 description 2
- 240000006661 Serenoa repens Species 0.000 description 2
- 235000005318 Serenoa repens Nutrition 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 235000003531 Smilax aspera Nutrition 0.000 description 2
- 240000009241 Smilax aspera Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000002634 Solanum Nutrition 0.000 description 2
- 241000207763 Solanum Species 0.000 description 2
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 2
- 241001517403 Spiranthes Species 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 240000001949 Taraxacum officinale Species 0.000 description 2
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 241000219793 Trifolium Species 0.000 description 2
- 240000000143 Turnera diffusa Species 0.000 description 2
- 241000607122 Uncaria tomentosa Species 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 235000007212 Verbena X moechina Moldenke Nutrition 0.000 description 2
- 235000001594 Verbena polystachya Kunth Nutrition 0.000 description 2
- 235000007200 Verbena x perriana Moldenke Nutrition 0.000 description 2
- 235000002270 Verbena x stuprosa Moldenke Nutrition 0.000 description 2
- 241000607598 Vibrio Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- 229950006790 adenosine phosphate Drugs 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 229940125708 antidiabetic agent Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 108010045569 atelocollagen Proteins 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 235000021324 borage oil Nutrition 0.000 description 2
- 239000010474 borage seed oil Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229940044199 carnosine Drugs 0.000 description 2
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 2
- 230000036232 cellulite Effects 0.000 description 2
- 229940059958 centella asiatica extract Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000008406 cosmetic ingredient Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 229940073499 decyl glucoside Drugs 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000024690 epidermis development Effects 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 229940011399 escin Drugs 0.000 description 2
- 229930186222 escin Natural products 0.000 description 2
- 229940093496 esculin Drugs 0.000 description 2
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 2
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 2
- 235000008524 evening primrose extract Nutrition 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 229940040461 lipase Drugs 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 230000001016 myotrophic effect Effects 0.000 description 2
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229940094912 palmitoyl tripeptide-5 Drugs 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000007030 peptide scission Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 201000003385 seborrheic keratosis Diseases 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- KZQSXALQTHVPDQ-UHFFFAOYSA-M sodium;butanedioate;hydron Chemical compound [Na+].OC(=O)CCC([O-])=O KZQSXALQTHVPDQ-UHFFFAOYSA-M 0.000 description 2
- 239000001589 sorbitan tristearate Substances 0.000 description 2
- 235000011078 sorbitan tristearate Nutrition 0.000 description 2
- 229960004129 sorbitan tristearate Drugs 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000000261 subcutaneous preadipocyte Anatomy 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 208000009056 telangiectasis Diseases 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000004753 textile Substances 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 108091006108 transcriptional coactivators Proteins 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 235000004952 turnera diffusa Nutrition 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 229940096998 ursolic acid Drugs 0.000 description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 2
- 230000001643 venotonic effect Effects 0.000 description 2
- GMBQZIIUCVWOCD-RHHRBMONSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S,16R,18R)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-16-ol Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 GMBQZIIUCVWOCD-RHHRBMONSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- PUHIYNTXUULLTL-YZYZGRISSA-N (2S)-4-amino-2-[[(2S)-2-[[(2S)-4-amino-2-(tetradecylcarbamoylamino)butanoyl]amino]-3-methylbutanoyl]amino]butanoic acid 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.CCCCCCCCCCCCCCNC(=O)N[C@@H](CCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCN)C(O)=O PUHIYNTXUULLTL-YZYZGRISSA-N 0.000 description 1
- QWWPCQGHWWNGET-LCVVDEIYSA-N (2r,3r,4s,5s,6r)-2-[[(2r,4as,4br,7s,10as)-7-[(1r)-1,2-dihydroxyethyl]-1,1,4a,7-tetramethyl-3,4,4b,5,6,9,10,10a-octahydro-2h-phenanthren-2-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O([C@H]1C([C@H]2CCC3=C[C@](C)(CC[C@H]3[C@]2(C)CC1)[C@@H](O)CO)(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWWPCQGHWWNGET-LCVVDEIYSA-N 0.000 description 1
- JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 1
- KFSJYZYQSZKRRQ-BYPYZUCNSA-N (2s)-2-(hydroxyamino)-4-methylsulfanylbutanoic acid Chemical compound CSCC[C@H](NO)C(O)=O KFSJYZYQSZKRRQ-BYPYZUCNSA-N 0.000 description 1
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 1
- RWLSBXBFZHDHHX-VIFPVBQESA-N (2s)-2-(naphthalen-2-ylamino)propanoic acid Chemical compound C1=CC=CC2=CC(N[C@@H](C)C(O)=O)=CC=C21 RWLSBXBFZHDHHX-VIFPVBQESA-N 0.000 description 1
- VEVRNHHLCPGNDU-MUGJNUQGSA-N (2s)-2-amino-5-[1-[(5s)-5-amino-5-carboxypentyl]-3,5-bis[(3s)-3-amino-3-carboxypropyl]pyridin-1-ium-4-yl]pentanoate Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-N 0.000 description 1
- LFXLWPKXAQBEEB-ZDUSSCGKSA-N (2s)-n-[2-(1h-indol-3-yl)ethyl]-5-oxopyrrolidine-2-carboxamide Chemical compound C=1NC2=CC=CC=C2C=1CCNC(=O)[C@@H]1CCC(=O)N1 LFXLWPKXAQBEEB-ZDUSSCGKSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- GMBQZIIUCVWOCD-DGBDVICSSA-N (3α,5α,25r)-spirostan-3-ol Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@@H](O)C[C@@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 GMBQZIIUCVWOCD-DGBDVICSSA-N 0.000 description 1
- KMACPCJUCHVVGP-FNRPHRCSSA-N (4S)-4-acetamido-5-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-carboxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(N)=O KMACPCJUCHVVGP-FNRPHRCSSA-N 0.000 description 1
- QGGBBQJHVCVVKM-XOBYPWAZSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-amino-3-carboxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amin Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(N)=O QGGBBQJHVCVVKM-XOBYPWAZSA-N 0.000 description 1
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 description 1
- RJZNPROJTJSYLC-LLINQDLYSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O RJZNPROJTJSYLC-LLINQDLYSA-N 0.000 description 1
- DJAHKBBSJCDSOZ-AJLBTXRUSA-N (5z,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one;(5e,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C/CCC(C)=O.CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O DJAHKBBSJCDSOZ-AJLBTXRUSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 description 1
- RUZIUYOSRDWYQF-HNNXBMFYSA-N (S)-glaucine Chemical compound CN1CCC2=CC(OC)=C(OC)C3=C2[C@@H]1CC1=C3C=C(OC)C(OC)=C1 RUZIUYOSRDWYQF-HNNXBMFYSA-N 0.000 description 1
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical group C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical group C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- GVEZIHKRYBHEFX-MNOVXSKESA-N 13C-Cerulenin Natural products CC=CCC=CCCC(=O)[C@H]1O[C@@H]1C(N)=O GVEZIHKRYBHEFX-MNOVXSKESA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- HCYFGRCYSCXKNQ-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxo-7-purinyl)acetic acid Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2 HCYFGRCYSCXKNQ-UHFFFAOYSA-N 0.000 description 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- XYWPNWJLJURBME-UHFFFAOYSA-N 2-[2-[4-(aminomethyl)-2,4-dimethoxycyclohexa-1,5-dien-1-yl]phenoxy]acetic acid Chemical compound C1=CC(CN)(OC)CC(OC)=C1C1=CC=CC=C1OCC(O)=O XYWPNWJLJURBME-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- KBHSAMYHDBBRKS-QTJGBDASSA-N 2-hydroxy-n-[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]benzamide Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)C1=CC=CC=C1O KBHSAMYHDBBRKS-QTJGBDASSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Aminopropanesulfonate Chemical compound NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- NBGQZFQREPIKMG-UHFFFAOYSA-N 3beta-hydroxy-beta-boswellic acid Natural products C1CC(O)C(C)(C(O)=O)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C NBGQZFQREPIKMG-UHFFFAOYSA-N 0.000 description 1
- ASNHGEVAWNWCRQ-UHFFFAOYSA-N 4-(hydroxymethyl)oxolane-2,3,4-triol Chemical compound OCC1(O)COC(O)C1O ASNHGEVAWNWCRQ-UHFFFAOYSA-N 0.000 description 1
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000521948 Acmella Species 0.000 description 1
- 208000003911 Acne Keloid Diseases 0.000 description 1
- 206010000503 Acne cystic Diseases 0.000 description 1
- 241000906543 Actaea racemosa Species 0.000 description 1
- 240000004246 Agave americana Species 0.000 description 1
- 235000008754 Agave americana Nutrition 0.000 description 1
- 235000011624 Agave sisalana Nutrition 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- 241000605447 Anemarrhena Species 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 229940122659 Angiogenesis stimulant Drugs 0.000 description 1
- 235000007755 Annona Nutrition 0.000 description 1
- 235000011518 Annona purpurea Nutrition 0.000 description 1
- 240000006199 Annona purpurea Species 0.000 description 1
- 241000001503 Anogeissus Species 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 235000016108 Argania sideroxylon Nutrition 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 241001448336 Asparagus filicinus Species 0.000 description 1
- 241000432811 Asparagus racemosus Species 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 235000002992 Betula pubescens Nutrition 0.000 description 1
- 241001520764 Betula pubescens Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- NBGQZFQREPIKMG-PONOSELZSA-N Boswellic acid Chemical compound C1C[C@@H](O)[C@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C NBGQZFQREPIKMG-PONOSELZSA-N 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 206010006242 Breast enlargement Diseases 0.000 description 1
- 206010006272 Breast mass Diseases 0.000 description 1
- SNCIAAAFBLUWEE-NMTVEPIMSA-N CSCC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(O)=O Chemical compound CSCC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(O)=O SNCIAAAFBLUWEE-NMTVEPIMSA-N 0.000 description 1
- 235000014138 Caesalpinia decapetala Nutrition 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000004173 Cathepsin G Human genes 0.000 description 1
- 108090000617 Cathepsin G Proteins 0.000 description 1
- 241000985665 Cecropia obtusifolia Species 0.000 description 1
- 235000013913 Ceratonia Nutrition 0.000 description 1
- 241001060815 Ceratonia Species 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 235000015493 Chenopodium quinoa Nutrition 0.000 description 1
- 235000007089 Chlorella vulgaris Nutrition 0.000 description 1
- 240000009108 Chlorella vulgaris Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 241001026287 Chrysanthellum indicum Species 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 235000018959 Chrysanthemum indicum Nutrition 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- 235000013306 Cistus creticus Nutrition 0.000 description 1
- 244000028508 Cistus creticus Species 0.000 description 1
- 235000000350 Cistus incanus Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 235000001938 Citrus medica Nutrition 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- IUDDKQPNTNOJIP-UHFFFAOYSA-N ClCl1[ClH]C=[C-][ClH]1 Chemical compound ClCl1[ClH]C=[C-][ClH]1 IUDDKQPNTNOJIP-UHFFFAOYSA-N 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 235000007460 Coffea arabica Nutrition 0.000 description 1
- 241000554434 Coleus xanthanthus Species 0.000 description 1
- 240000003890 Commiphora wightii Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000012437 Copper-Transporting ATPases Human genes 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241001648676 Croton lechleri Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 244000019459 Cynara cardunculus Species 0.000 description 1
- 235000019106 Cynara scolymus Nutrition 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- QWWPCQGHWWNGET-ZPGRLJJOSA-N Darutoside Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](CO)O1)[C@H]1C(C)(C)[C@H]2[C@](C)([C@@H]3C(=C[C@]([C@H](O)CO)(C)CC3)CC2)CC1 QWWPCQGHWWNGET-ZPGRLJJOSA-N 0.000 description 1
- 241000208296 Datura Species 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 108010046331 Deoxyribodipyrimidine photo-lyase Proteins 0.000 description 1
- 206010051651 Dermatitis papillaris capillitii Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 241000195633 Dunaliella salina Species 0.000 description 1
- 208000001708 Dupuytren contracture Diseases 0.000 description 1
- 239000004266 EU approved firming agent Substances 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- 101000877447 Enterobacteria phage T4 Endonuclease V Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 241000195950 Equisetum arvense Species 0.000 description 1
- 239000005768 Equisetum arvense L. Substances 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000266331 Eugenia Species 0.000 description 1
- 241000195619 Euglena gracilis Species 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 229920002444 Exopolysaccharide Polymers 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010049290 Feminisation acquired Diseases 0.000 description 1
- 208000034793 Feminization Diseases 0.000 description 1
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 241000557129 Glaucium Species 0.000 description 1
- DABPOQZSGVNAAS-UHFFFAOYSA-N Glaucocalactone Natural products O=CC12C3C(C4)OC(=O)C2C(C)(C)CCC1OC(=O)C13CC4C(=C)C1OC(=O)C DABPOQZSGVNAAS-UHFFFAOYSA-N 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 235000004341 Gossypium herbaceum Nutrition 0.000 description 1
- 240000002024 Gossypium herbaceum Species 0.000 description 1
- 241000222684 Grifola Species 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 241000208341 Hedera Species 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 235000003325 Ilex Nutrition 0.000 description 1
- 241000209035 Ilex Species 0.000 description 1
- 244000188472 Ilex paraguariensis Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000138806 Impages Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 241000201323 Kigelia Species 0.000 description 1
- 208000006264 Korsakoff syndrome Diseases 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZUKPVRWZDMRIEO-VKHMYHEASA-N L-cysteinylglycine Chemical compound SC[C@H]([NH3+])C(=O)NCC([O-])=O ZUKPVRWZDMRIEO-VKHMYHEASA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- PTNJRKBWIYNFSY-UHFFFAOYSA-N Lirinin-O-methyl-ether Natural products COc1ccc-2c(CC3N(C)CCc4cc(OC)c(OC)c-2c34)c1 PTNJRKBWIYNFSY-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 244000061323 Lycopersicon pimpinellifolium Species 0.000 description 1
- 235000002541 Lycopersicon pimpinellifolium Nutrition 0.000 description 1
- 241000208473 Macadamia ternifolia Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003394 Malpighia glabra Species 0.000 description 1
- 235000014837 Malpighia glabra Nutrition 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000005321 Marrubium vulgare Nutrition 0.000 description 1
- 244000137850 Marrubium vulgare Species 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 208000035155 Mitochondrial DNA-associated Leigh syndrome Diseases 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 244000132436 Myrica rubra Species 0.000 description 1
- 241000498779 Myristica Species 0.000 description 1
- 241001057584 Myrrha Species 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GMBQZIIUCVWOCD-PUHUBZITSA-N Neotigogenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 GMBQZIIUCVWOCD-PUHUBZITSA-N 0.000 description 1
- 208000030995 Nevus comedonicus syndrome Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- WLHBRQYVZLNQFE-UHFFFAOYSA-N O[S+]1C2=CC=CC=C2N=C1 Chemical compound O[S+]1C2=CC=CC=C2N=C1 WLHBRQYVZLNQFE-UHFFFAOYSA-N 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 240000008916 Oenothera biennis Species 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 241001184198 Orthosiphon Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108091008767 PPARγ2 Proteins 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- DLUTTXMPJCVUFR-HJCIYZGTSA-N Parillin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@@H]1C[C@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@@H](C)CC1)O5)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DLUTTXMPJCVUFR-HJCIYZGTSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 235000010617 Phaseolus lunatus Nutrition 0.000 description 1
- 244000100170 Phaseolus lunatus Species 0.000 description 1
- 235000010659 Phoenix dactylifera Nutrition 0.000 description 1
- 244000104275 Phoenix dactylifera Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 244000273256 Phragmites communis Species 0.000 description 1
- 241000831729 Phyllacantha Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 235000016787 Piper methysticum Nutrition 0.000 description 1
- 240000005546 Piper methysticum Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940123575 Protein synthesis stimulant Drugs 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 235000010674 Prunella vulgaris Nutrition 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 235000009001 Quillaja saponaria Nutrition 0.000 description 1
- 241001454523 Quillaja saponaria Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241001478280 Rahnella Species 0.000 description 1
- 102000034527 Retinoid X Receptors Human genes 0.000 description 1
- 108010038912 Retinoid X Receptors Proteins 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- UEJYSALTSUZXFV-SRVKXCTJSA-N Rigin Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O UEJYSALTSUZXFV-SRVKXCTJSA-N 0.000 description 1
- QMQIQBOGXYYATH-IDABPMKMSA-N Ruscogenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)[C@H](O)C[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 QMQIQBOGXYYATH-IDABPMKMSA-N 0.000 description 1
- BSUPFYRQXCQGLJ-UHFFFAOYSA-N Ruscogenin Natural products CC1CCC2(OC1)OC3C(O)C4C5CC=C6CC(O)CC(O)C6(C)C5CCC4(C)C3C2C BSUPFYRQXCQGLJ-UHFFFAOYSA-N 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 235000002912 Salvia officinalis Nutrition 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 241001529553 Scoparia <angiosperm> Species 0.000 description 1
- 244000297627 Senna alata Species 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000589196 Sinorhizobium meliloti Species 0.000 description 1
- 235000008981 Smilax officinalis Nutrition 0.000 description 1
- 240000002493 Smilax officinalis Species 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 244000194806 Solanum sisymbriifolium Species 0.000 description 1
- 235000018724 Solanum sisymbriifolium Nutrition 0.000 description 1
- 240000003829 Sorghum propinquum Species 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 241001126796 Sphacelaria Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241001300423 Strophostyles Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000006754 Taraxacum officinale Nutrition 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 235000017517 Tephrosia purpurea Nutrition 0.000 description 1
- 240000004429 Tephrosia purpurea Species 0.000 description 1
- 241000219161 Theobroma Species 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 241001521901 Tribulus lanuginosus Species 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 235000007251 Triticum monococcum Nutrition 0.000 description 1
- 240000000581 Triticum monococcum Species 0.000 description 1
- 235000009206 Turnera diffusa Nutrition 0.000 description 1
- LQSNPVIQIPKOGP-UHFFFAOYSA-N UNPD159785 Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=CC2=O LQSNPVIQIPKOGP-UHFFFAOYSA-N 0.000 description 1
- 241001473768 Ulmus rubra Species 0.000 description 1
- 241000894477 Ulva compressa Species 0.000 description 1
- 235000018718 Verbena officinalis Nutrition 0.000 description 1
- 241000219977 Vigna Species 0.000 description 1
- GVBNSPFBYXGREE-CXWAGAITSA-N Visnadin Chemical compound C1=CC(=O)OC2=C1C=CC1=C2[C@@H](OC(C)=O)[C@@H](OC(=O)[C@H](C)CC)C(C)(C)O1 GVBNSPFBYXGREE-CXWAGAITSA-N 0.000 description 1
- GVBNSPFBYXGREE-UHFFFAOYSA-N Visnadine Natural products C1=CC(=O)OC2=C1C=CC1=C2C(OC(C)=O)C(OC(=O)C(C)CC)C(C)(C)O1 GVBNSPFBYXGREE-UHFFFAOYSA-N 0.000 description 1
- 235000001667 Vitex agnus castus Nutrition 0.000 description 1
- 244000063464 Vitex agnus-castus Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 244000116042 Yucca brevifolia Species 0.000 description 1
- 235000004519 Yucca filamentosa Nutrition 0.000 description 1
- 241000180530 Yucca filifera Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- OEWBEINAQKIQLZ-CMRBMDBWSA-N [(2s)-2-[(2r)-3,4-bis(2-hexyldecanoyloxy)-5-oxo-2h-furan-2-yl]-2-(2-hexyldecanoyloxy)ethyl] 2-hexyldecanoate Chemical compound CCCCCCCCC(CCCCCC)C(=O)OC[C@H](OC(=O)C(CCCCCC)CCCCCCCC)[C@H]1OC(=O)C(OC(=O)C(CCCCCC)CCCCCCCC)=C1OC(=O)C(CCCCCC)CCCCCCCC OEWBEINAQKIQLZ-CMRBMDBWSA-N 0.000 description 1
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 description 1
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229950003769 acefylline Drugs 0.000 description 1
- HSUGRPOJOBRRBK-SXBSVMRRSA-N acetic acid;(2s)-n-[(2s)-4-amino-1-(benzylamino)-1-oxobutan-2-yl]-1-(3-aminopropanoyl)pyrrolidine-2-carboxamide Chemical compound CC(O)=O.CC(O)=O.N([C@@H](CCN)C(=O)NCC=1C=CC=CC=1)C(=O)[C@@H]1CCCN1C(=O)CCN HSUGRPOJOBRRBK-SXBSVMRRSA-N 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 description 1
- 229940078033 acetyl octapeptide-3 Drugs 0.000 description 1
- 229940086540 acetyl tetrapeptide-9 Drugs 0.000 description 1
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000000909 amidinium group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
- UKFWSNCTAHXBQN-UHFFFAOYSA-N ammonium iodide Chemical compound [NH4+].[I-] UKFWSNCTAHXBQN-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229930191283 anemarrhena Natural products 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940115137 anisum extract Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000005427 anthranyl group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229920000617 arabinoxylan Polymers 0.000 description 1
- 229940033244 argania spinosa leaf extract Drugs 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000010216 breast implantation Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000001593 brown adipocyte Anatomy 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
- GVEZIHKRYBHEFX-UHFFFAOYSA-N caerulein A Natural products CC=CCC=CCCC(=O)C1OC1C(N)=O GVEZIHKRYBHEFX-UHFFFAOYSA-N 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 229960001713 canagliflozin Drugs 0.000 description 1
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical group OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229960003362 carbutamide Drugs 0.000 description 1
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940082906 centella asiatica leaf extract Drugs 0.000 description 1
- 229940044176 ceramide 3 Drugs 0.000 description 1
- 229940043431 ceratonia Drugs 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229950005984 cerulenin Drugs 0.000 description 1
- GVEZIHKRYBHEFX-NQQPLRFYSA-N cerulenin Chemical compound C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O GVEZIHKRYBHEFX-NQQPLRFYSA-N 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 235000009347 chasteberry Nutrition 0.000 description 1
- 210000003467 cheek Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000003467 chloride channel stimulating agent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000005301 cimicifuga racemosa Nutrition 0.000 description 1
- 238000010549 co-Evaporation Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000012679 convergent method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 239000003581 cosmetic carrier Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- GCFAUZGWPDYAJN-UHFFFAOYSA-N cyclohexyl 3-phenylprop-2-enoate Chemical compound C=1C=CC=CC=1C=CC(=O)OC1CCCCC1 GCFAUZGWPDYAJN-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000011928 denatured alcohol Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- 229940117973 dimethylmethoxy chromanol Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 244000013123 dwarf bean Species 0.000 description 1
- 150000002061 ecdysteroids Chemical class 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 229940096118 ella Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- QMQIQBOGXYYATH-UHFFFAOYSA-N epiruscogenin Natural products CC1C(C2(CCC3C4(C)C(O)CC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 QMQIQBOGXYYATH-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229940045761 evening primrose extract Drugs 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 235000021130 excess caloric intake Nutrition 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 235000011990 fisetin Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000014106 fortified food Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229940106580 ginkgo biloba leaf extract Drugs 0.000 description 1
- 229940113086 glaucine Drugs 0.000 description 1
- 229930004041 glaucine Natural products 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 150000002305 glucosylceramides Chemical class 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 235000021331 green beans Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- BNRNAKTVFSZAFA-UHFFFAOYSA-N hydrindane Chemical compound C1CCCC2CCCC21 BNRNAKTVFSZAFA-UHFFFAOYSA-N 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 229960004135 idebenone Drugs 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- KEOITPILCOILGM-LLJOFIFVSA-N kalopanaxsaponin A Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(CC[C@]6(CCC(C)(C)C[C@H]6C5=CC4)C(O)=O)C)(C)CC3)(C)CC2)(C)CO)OC[C@H](O)[C@@H]1O KEOITPILCOILGM-LLJOFIFVSA-N 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 125000002669 linoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005645 linoleyl group Chemical group 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960001093 lixisenatide Drugs 0.000 description 1
- 108010004367 lixisenatide Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 235000020331 mate tea Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000003531 maternally-inherited Leigh syndrome Diseases 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 238000000694 mesotherapy Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960003365 mitiglinide Drugs 0.000 description 1
- WPGGHFDDFPHPOB-BBWFWOEESA-N mitiglinide Chemical compound C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)O)C1=CC=CC=C1 WPGGHFDDFPHPOB-BBWFWOEESA-N 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- 229920000847 nonoxynol Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- PLAPMLGJVGLZOV-VPRICQMDSA-N orientin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=CC2=O PLAPMLGJVGLZOV-VPRICQMDSA-N 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- VWMVAQHMFFZQGD-UHFFFAOYSA-N p-Hydroxybenzyl acetone Natural products CC(=O)CC1=CC=C(O)C=C1 VWMVAQHMFFZQGD-UHFFFAOYSA-N 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- DLUTTXMPJCVUFR-UHFFFAOYSA-N parillin Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CCC4CC5OC(C(C(O)C1OC2C(C(O)C(O)C(C)O2)O)OC2C(C(O)C(O)C(CO)O2)O)OC1COC1OC(CO)C(O)C(O)C1O DLUTTXMPJCVUFR-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 108010060054 peroxisome-proliferator-activated receptor-gamma coactivator-1 Proteins 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 108010090674 phenylalanyl-glycyl-histidyl-statyl-alanyl-phenylalanine methyl ester Proteins 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 229930000756 phytoceramide Natural products 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 239000001909 pimpinella anisum Substances 0.000 description 1
- XIPFMBOWZXULIA-UHFFFAOYSA-N pivalamide Chemical compound CC(C)(C)C(N)=O XIPFMBOWZXULIA-UHFFFAOYSA-N 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002189 poly(glycerol 1-O-monomethacrylate) polymer Polymers 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 229940093916 potassium phosphate Drugs 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
- 229960004457 pramlintide acetate Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000001651 pyrus cydonia seed extract Substances 0.000 description 1
- 244000022778 quail grass Species 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229940092385 radish extract Drugs 0.000 description 1
- NJGBTKGETPDVIK-UHFFFAOYSA-N raspberry ketone Chemical compound CC(=O)CCC1=CC=C(O)C=C1 NJGBTKGETPDVIK-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940118867 remodulin Drugs 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 210000004708 ribosome subunit Anatomy 0.000 description 1
- 108010091078 rigin Proteins 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229940109990 ruscogenin Drugs 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940077859 salicyloyl phytosphingosine Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 239000010018 saw palmetto extract Substances 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- SCPYDCQAZCOKTP-UHFFFAOYSA-N silanol Chemical compound [SiH3]O SCPYDCQAZCOKTP-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 210000001189 slow twitch fiber Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940057950 sodium laureth sulfate Drugs 0.000 description 1
- 229940006186 sodium polystyrene sulfonate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 229940069755 soybean germ extract Drugs 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 description 1
- 108010048573 taspoglutide Proteins 0.000 description 1
- 229950007151 taspoglutide Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229950006156 teprenone Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000476 thermogenic effect Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229930193981 timosaponin Natural products 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- IQKAWAUTOKVMLE-ZSESPEEFSA-M treprostinil sodium Chemical compound [Na+].C1=CC=C(OCC([O-])=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 IQKAWAUTOKVMLE-ZSESPEEFSA-M 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical group CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
- 125000005500 uronium group Chemical group 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229960000821 visnadine Drugs 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 238000011680 zucker rat Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/068—Microemulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Birds (AREA)
Description
本発明の理解を容易にするために、本発明に関して用いられるいくつかの用語及び表現の意味を記載する。
本発明のペプチドは、一般式(I):
R1−Wn−Xm−AA1−AA2−AA3−AA4−AA5−AA6−Yp−Zq−R2(I)
それらの立体異性体、その混合物及び/又はそれらの美容的若しくは薬学的に許容可能な塩によって定義され、これは、以下を特徴とする:
AA1は、−His−及び−Ser−からなる群から選択され;
AA2は、−Ile−及び−Val−からなる群から選択され;
AA3は、−Tyr−及び−Val−からなる群から選択され;
AA4は、−Val−であり;
AA5は、−Ala−、−Arg−及び−Gly−からなる群から選択され;
AA6は、−Thr−及び−Val−からなる群から選択され;
W、X、Y、Zは、アミノ酸であり、互いに独立してそれらの中から選択され;
n、m、p及びqは、互いに独立してそれらの中から選択され、0又は1の値を有し;
n+m+p+qは、2以下であり;
R1は、H、置換又は非置換の非環式脂肪族基、置換又は非置換アリシクリル、置換又は非置換ヘテロシクリル、置換又は非置換ヘテロアリールアルキル、置換又は非置換アリール、置換又は非置換アラルキル及びR5−CO−からなる群から選択され、ここで、R5は、H、置換又は非置換の非環式脂肪族基、置換又は非置換アリシクリル、置換又は非置換アリール、置換又は非置換アラルキル、置換又は非置換ヘテロシクリル、及び置換又は非置換ヘテロアリールアルキルからなる群から選択され;
R2は、−NR3R4、−OR3及び−SR3からなる群から選択され、ここで、R3及びR4は、独立して、H、置換又は非置換の非環式脂肪族基、置換又は非置換アリシクリル、置換又は非置換ヘテロシクリル、置換又は非置換ヘテロアリールアルキル、置換又は非置換アリール、及び置換又は非置換アラルキルからなる群から選択され;
ただし、R1及びR2は、αアミノ酸ではないものとする。
本発明のペプチド、それらの立体異性体、又はそれらの美容的若しくは薬学的に許容可能な塩の合成は、先行技術において公知の従来の方法に従って実施することができ、そのような方法として、例えば、以下を用いたものがある:固相ペプチド合成法[Stewart J.M.and Young J.D.,“Solid Phase Peptide Synthesis,2nd edition”,(1984),Pierce Chemical Company,Rockford,Illinois;Bodanzsky M.,Bodanzsky A.“The practice of Peptide Synthesis”,(1984),Springer Verlag, New Cork;Lloyd−Williams P.,Albericio F.,Giralt E.“Chemical Approaches to the Synthesis of Peptides and Proteins”,(1997),CRC,Boca Raton,FL,USA]、液相合成、固相合成法と液相合成法の組合せ、又は酵素的合成法[Kullmann W.,“Proteases as catalysts for enzymic syntheses of opioid peptides”,(1980),J.Biol.Chem.,255,8234−8238]。ペプチドはまた、所望の配列を産生させることを目的とする生物工学的方法によって作製することもできるし、又は、動物、真菌、若しくは好ましくは植物由来のタンパク質の制御された加水分解により、少なくとも所望の配列を含むペプチド断片を遊離させることによって作製することもできる。
−N末端が保護され、C末端が遊離であるアミノ酸を、N末端が遊離であり、C末端が保護されているか、又は固体支持体に結合しているアミノ酸とカップリングするステップ;
−N末端の保護基を除去するステップ;
−所望のペプチド配列が得られるまで、配列のカップリングと、N末端の保護基の除去を繰り返すステップ;
−C末端の保護基を除去するか、又は固体支持体を切断するステップ
を含む。
本発明のペプチドは、PGC−1αを調節するために、本ペプチドと、哺乳動物の身体、好ましくはヒトの身体の作用部位とを接触させるあらゆる手段によって、これらのペプチドを含有する組成物の形態で、投与することができる。
tus))根エキス、マルトデキストリン、シリカ、Tea−ヨウ化水素酸塩、プロピレングリコール、セイヨウヅタ(Ivy)(ヘデラ・へリックス(Hedera Helix))エキス、カルニチン、エスシン、トリペプチド−1、キサンタンガム、カラギーナン(Carrageenan)(トチャカ(Chondrus Crispus))、ジソジウムEDTA](水、グリセリン、レシチン、カフェイン、ナギイカダ(Butcher’s Broom)(ルスクス・アクレアツス(Ruscus Aculeatus))根エキス、マルトデキストリン、シリカ、トリエタノールアミンヨウ化水素酸塩、プロピレングリコール、セイヨウヅタ(Ivy)エキス(ヘデラ・へリックス(Hedera Helix))、カルニチン、エスシン、トリペプチド−1、キサンタンガム、カラギーナン(Carrageenan)(トチャカ(Chondrus Crispus))、EDTA(ジソジウム)(Lipotecにより市販)、Iso−Slim Complex[INCI:ダイズイソフラボン、カフェイン、カルニチン、スピルリナ・プラテンシス(Spirulina Platensis)エキス、ポリソルベート80、アルコール、フェノキシエタノール、アクア]、Happybelle−PE[INCI:レシチン、セイヨウニンジンボク(Vitex Agnus Castus)エキス、グリセリン、アスコルビルテトライソパルミテート、トコフェロール、カプリル酸/カプリン酸トリグリセリド、シクロデキストリン、アルコール、水]若しくはAmaraShape[INCI:レシチン、カフェイン、オレンジビター(Citrus Aurantium Amara)エキス、ペンチレングリコール、アルコール、水](Mibelle Biochemistryにより市販)、Regu(登録商標)−Slim[INCI:マルトデキストリン、カフェイン、ガラナ(Paullinia Cupana)種子エキス、カルニチン、微結晶セルロース、システイン酸、スルホン酸パンテイン]若しくはRegu(登録商標)−Shape[INCI:異性化リノール酸、レシチン、グリセリン、ポリソルベート80](Pentapharm/DSMにより市販)、Voluplus(商標)[INCI:マカデミアナッツ(Macadamia Ternifolia Seed)油、メースリグナン、トコフェロール]、Provislim(商標)[INCI:プロパンジオール、水(アクア)、フィセチン、ラズベリーケトン]、Noline[INCI:メースリグナン(ナツメグ(Myristica fragans))]、Myriceline[INCI:ジヒドロミリセチン]若しくはDrenalip[INCI:ルスクス・アクレアツス(Ruscus Aculeatus)根エキス、レモン(Citrus Medica Limonum)皮エキス、アキノキリンソウ(Solidago Virgaurea)エキス、キバナ・オウギ(Astragalus Membranaceus)根エキス](Provitalにより市販)、Actisculpt[INCI:コンミフォラ・ミルラ(Commiphora Myrrha)エキス、コリウス・フォルスコリ(Coleus Forskohlii)根エキス](Questにより市販)、Perfeline(登録商標)[INCI:水、カルニチン、カフェイン、ルスクス・アクレアツス(Ruscus Aculeatus)エキス]、CellActive(登録商標)Shape[INCI:クロレラ(Chlorella Vulgaris)/シロバナルーピン(Lupinus Albus)タンパク質発酵物、コリウス・フォルスコリ(Coleus Forskohlii)、カフェイン]又はCellActive(登録商標)Form[INCI:マンゴスチン(Garcinia Mangostana)皮エキス、クロレラ(Chlorella Vulgaris)/シロバナルーピン(Lupinus Albus)タンパク質発酵物、マルメロ(Pyrus Cydonia)種子エキス](Rahnにより市販)、ProContour(商標)[INCI:水、アルコール、レシチン、カフェイン、カルニチン、ツボクサ(Centella Asiatica)葉エキス、リン酸カリウム、コリウス・フォルスコリ(Coleus Forskohlii)根エキス](Rovi Cosmeticsにより市販)、Volufiline(商標)[INCI:ハスナゲ(Anemarrhenae asphodeloides)(根)エキス]、Unislim(商標)[INCI:マテ茶(Ilex Paraguariensis)(葉)エキス、水、ブチレングリコール、コーヒーノキ(Coffea Arabica)(コーヒー)種子エキス(豆)、PEG−60アーモンドグリセリド、グリセリン、セチルヒドロキシエチルセルロース]、Redulite(商標)[INCI:グリセリン、アクア、エトキシジグリコール、サムブクス・ニグラ(Sambucus Nigra)、ポリアクリル酸ナトリウム]、Pleurimincyl(商標)[INCI:カフェイン(Caffeine)、マンシュウサイコ(Bupleurum Chinensis)エキス]、Phytotal(商標)SL[INCI:グリセリン、ベルベナ・オフィシナリス(Verbena Officinali)エキス、ブチレングリコール、サムブクス・ニグラ(Sambucus Nigra)花エキス、ユーゲニア・カリオフィルス(Eugenia Caryophyllus)(クローブ(Clove))花エキス、レシチン]、Phytosonic(商標)[INCI:アクア、ミドリムシ(Euglena Gracilis)エキス、カフェイン、ツノゲシ(Glaucium Flavum)葉エキス]、Ovaliss(商標)[INCI:グリセリン、アクア、ヤシ油アルキルグリコシド、カプリリルグリコール、アルコール、グラウシン]、Lipocare(商標)[INCI:カフェイン、コエンザイムA、マンシュウサイコ(Bupleurum Chinensis)エキス]、Cyclolipase(商標)[INCI:ポリメタクリル酸グリセリル、水、カフェイン、リパーゼ、リン酸アデノシン]、Coaxel(商標)[INCI:カフェイン、コエンザイムA、カルニチン、水、グリセリン]若しくはBodyfit(商標)[INCI:グリセリン、アクア(水)、ヤシ油アルキルグリコシド、カプリリルグリコール、アルコール、グラウシン](Sederma/Crodaにより市販)、Voluform[INCI:パルミトイルイソロイシン]、 Adiposlim[INCI:ラウリン酸ソルビタン、ライロイルプロリン]若しくはAdipoless[INCI:ブチレングリコール、キノア(Chenopodium Quinoa)種子エキス](Seppicにより市販)、Slimactive(登録商標)[INCI:ペウムス・ボルドゥス(Peumus Boldus)葉エキス]、Remoduline(登録商標)[INCI:オレンジビター(Citrus Aurantium Amara)花エキス]、Pro−Sveltyl[INCI:ネルビウム・スペシオスム(Nelumbium Speciosum)エキス]、Biosculptine(登録商標)[INCI:加水分解ケイトウ(Celosia Cristata)花/種子エキス、加水分解プルネラ・ブルガリス(Prunella Vulgaris)エキス]若しくはAffiness(登録商標)[INCI:加水分解コリアンダー(Coriandrum Sativum)果実エキス、オレンジスイート(Citrus Aurantium Dulcis)(オレンジ) 果実エキス](Silabにより市販)、Delipidol[INCI:チロシルプニケート]、Guaraslim(登録商標)[INCI:ブチレングリコール、水、カフェイン、ガラナ(Paullinia Cupana)種子エキス、ムイラブアマ(Ptychopetalum Olacoides)樹皮エキス]若しくはCaobromine(登録商標)[INCI:テオブロマ・カカオ(Theobroma Cocoa)外皮エキス](Solabiaにより市販)、Abdoliance[INCI:パルミチン酸スクロース、ポリソルベート20、リノール酸グリセリル、ガラナ(Paullinia Cupana)種子エキス、マルトデキストリン、アーモンド(Prunus Amygdalus Dulcis)(スイートアーモンド)油、レシチン、水、オレンジビター(Citrus Aurantium Amara)(ビターオレンジ)皮エキス、フェノキシエタノール、トコフェロール]、Betaphroline[INCI:ナンバンクサフジ(Tephrosia Purpurea)種子エキス]若しくはCommipheroline[INCI:ガムググル(Commiphora Mukul)樹脂エキス](Solianceにより市販)、UCPeptide(商標)V[INCI:水、ブチレングリコール、ペンタペプチド]若しくはATPeptide(商標)IS[INCI:トリペプチド−3](Vincience/ISPにより市販)、又はこれらの混合物も、美容的若しくは薬学的に有効な量で含有する、美容又は医薬組成物に関する。
本発明の一態様は、PGC−1αの調節のための美容又は医薬組成物の調製における、一般式(I)の少なくとも1つのペプチド、その立体異性体、その混合物及び/又はその美容的若しくは薬学的に許容可能な塩の使用に関する。
試薬及び溶媒はすべて合成グレードであり、追加の処理を行うことなく使用する。
アミノ酸に用いられる略称は、Eur.J.Biochem.(1984)138:937に概説されている1983 IUPAC−IUB合同委員会生化学命名法提案(Joint Commission on Biochemical Nomenclature recommendations)の規則に従う。(R)は、樹脂;2,6−ジClZは、2,6−ジクロロベンジル;2−BrZは、2−ブロモベンジルオキシカルボニル;2−ClTrt(R)は、2−クロロトリチル樹脂;Acは、アセチル;Adpocは、1−(1−アダマンチル)−1−メチルエトキシ−カルボニル;AIDSは、後天性免疫不全症候群;Alaは、アラニン;Allは、アリル;Allocは、アリルオキシカルボニル;AMは、2−[4−アミノメチル−(2,4−ジメトキシフェニル)]フェノキシ酢酸;Argは、アルギニン;Bocは、tert−ブチルオキシカルボニル;Bomは、ベンジルオキシメチル;Bzlは、ベンジル;cAMPは、環状アデノシン一リン酸;Cbzは、カルボキシベンジル;cHxは、シクロヘキシル;ClZは、2−クロロベンジル;C末端は、カルボキシ末端;DCMは、ジクロロメタン;Ddeは、N−[1−(4,4−ジメチル−2,6−ジオキソシクロヘクス−1−イリデン)エチル;DIEAは、N,N’−ジイソプロピルエチルアミン;DIPCDIは、N,N’−ジイソプロピルカルボジイミド;Dmabは、4−(N−[1−(4,4−ジメチル−2,6−ジオキソシクロヘキシリデン)−3−メチルブチル]アミノ)ベンジル;DMFは、N,N−ジメチルホルムアミド;DNAは、デオキシリボ核酸;Dnpは、2,4−ジニトロフェノール;EDTAは、エチレンジアミン四酢酸;equivは、当量;ESI−MSは、エレクトロスプレーイオン化質量分析;Fmは、フルオレニルメチル;Fmocは、9−フルオレニルメチルオキシカルボニル;Glyは、グリシン;Hisは、ヒスチジン;HOAtは、1−ヒドロキシ−7−アザベンゾトリアゾール;HOBtは、1−ヒドロキシベンゾトリアゾール;HPLCは、高性能液体クロマトグラフィー;HSP70は、熱ショックタンパク質70kDa;Ileは、イソロイシン;INCIは、International Nomenclature of Cosmetic Ingredients;ivDdeは、1−(4,4−ジメチル−2,6−ジオキソシクロヘキリリデン)−3−メチル−ブチル;MBHAは、p−メチルベンズヒドリルアミン;Meは、メチル;MeCNは、アセトニトリル;MeOHは、メタノール;mRNAは、メッセンジャーリボ核酸;Mtrは、4−メトキシ−2,3,6−トリメチルベンゼンスルホニル;Mtsは、メシチレンスルホニル;Mttは、メトキシトリチル若しくはメチルトリチル;N末端は、アミノ末端;PALは、5−(4−アミノメチル−3,5−ジメトキシフェノキシ)吉草酸;Palmは、パルミトイル;Pbfは、2,2,4,6,7−ペンタメチルジヒドロベンゾフラン−5−スルホニル;PCRは、ポリメラーゼ連鎖反応;PDM−2は、前駆脂肪細胞分化用培地;PGC−1αは、PPARγコアクチベーター1α;PGM(商標)−2は、脂肪前駆細増殖培地;pmcは、2,2,5,7,8−ペンタメチルクロマン−6−スルホニル;pNZは、p−ニトロベンジルオキシカルボニル;PPARγは、ペロキソーム増殖剤活性化受容体γ;q.s.は、十分量;q.s.p.は、〜に対する十分量;RNAは、リボ核酸;Serは、セリン;tBuは、tert−ブチル;Teocは、2−(トリメチルシリル)エチルオキシカルボニル;TFAは、トリフルオロ酢酸;THFは、テトラヒドロフラン;Thrは、トレオニン、TISは、トリイソプロピルシラン;Tosは、トシル又はp−トルエンスルホニル;Trocは、2,2,2−トリクロロエトキシカルボニル;Trtは、トリフェニルメチル若しくはトリチル;Tyrは、チロシン;Valは、バリン;Zは、ベンジルオキシカルボニル。
合成プロセスはすべて、多孔性ポリエチレンディスクを取り付けたポリプロピレンシリンジにおいて実施した。試薬及び溶媒はすべて、合成グレードであり、追加の処理を行うことなく使用した。溶媒及び可溶性試薬は、吸引によって除去した。Fmoc基は、ピペリジン−DMF(2:8、v/v)で除去した(1x1分、1x5分、5mL/g樹脂)[LloydWilliams P.et al.(1997)“Chemical Approaches to the Synthesis of Peptides and Proteins”CRC,Boca Raton(FL,USA)]。脱保護、カップリング、及び再度の脱保護の各ステップ間の洗浄は、各回に10mL溶媒/g樹脂のDMF(3x1分)を用いて実施した。カップリング反応は、3mL溶媒/g樹脂で行った。カップリングの制御は、ニンヒドリン試験[Kaiser E.et al.,(1970)Anal.Biochem.34:595598]又はクロラニル試験[Christensen T.(1979)Acta Chem.Scand.33B:763766]の実施により行った。合成反応及び洗浄はすべて、25℃で実施した。
Fmoc−Wn−Xm−AA1−AA2−AA3−AA4−AA5−AA6−Yp−Zq−O−2−ClTrt−(R)(AA1は、−L−His−又は−L−Ser−であり;AA2は、−L−Ile−又は−L−Val−であり;AA3は、−L−Tyr−又は−L−Val−であり;AA4は、−L−Val−であり;AA5は、−L−Ala−、−L−Arg−又は−Gly−であり;AA6は、−L−Thr−又は−L−Val−であり;n、m、p及びqは、0である)の取得
3.50gのFmoc−L−Thr(tBu)−OH又は2.99gのFmoc−Val−OH(8.8mモル;1当量)を55mLのDCMに溶解させて、これに1.3mLのDIEA(7.6mモル;0.86当量)を添加したものを、乾燥2−クロロトリチル樹脂(5.5g;8.8mモル)にカップリングさせた。これらを5分間撹拌した後、2.5mLのDIEAを添加した(14.6mモル;1.66当量)。この混合物を40分間反応させた。4.4mLのMeOHで処理することによって、残留塩化物基をブロックした。
Fmoc−Wn−Xm−AA1−AA2−AA3−AA4−AA5−AA6−Yp−Zq−O−AM−MBHA−(R)(AA1は、−L−His−又は−L−Ser−であり;AA2は、−L−Ile−又は−L−Val−であり;AA3は、−L−Tyr−又は−L−Val−であり;AA4は、−L−Val−であり;AA5は、−L−Ala−、−L−Arg−又は−Gly−であり;AA6は、−L−Thr−又は−L−Val−であり;n、m、p及びqは、0である)の取得
0.73mモル/g(5mモル)で官能化した6.85gのFmoc−AM−MBHA樹脂を、Fmoc基を除去する目的で、記載した一般的プロトコルに従ってピペリジン−DMFで処理した。4.97gのFmoc−L−Thr(tBu)−OH又は4.24gのFmoc−L−Val−OH(12.5mモル;2.5当量)を、DIPCDI(1.93mL;12.5mモル;2.5当量)及びHOBt(1.93g;12.5mモル;2.5当量)の存在下、溶媒としてDMFを用いて、1時間にわたり脱保護樹脂に組み込んだ。
FmocN末端保護基除去のための一般的手順
実施例1及び2で得られたペプチド樹脂のN末端Fmoc基を全般的方法で述べたように、脱保護した(DMF中の20%ピペリジン、1x5分+1x20分)。ペプチド樹脂をDMF(5x1分)、DCM(4x1分)、ジエチルエーテル(4x1分)で洗浄した後、真空下で乾燥させた。
実施例3で得られたペプチド樹脂上にR1パルミトイル基を導入するための手順
DMF(1mL)に予め溶解させたパルミチン酸(10mモル;10当量)2.56gを、1.53gのHOBt(10mモル;10当量)及び1.54mLのDIPCDI(10mモル;10当量)の存在下で、実施例3で得られたペプチド樹脂1mモル上に添加した。これらを15時間にわたって反応させた後、得られた樹脂をTHF(5x1分)、DCM(5x1分)、DMF(5x1分)、MeOH(5x1分)、DMF(5x1分)、THF(5x1分)、DMF(5x1分)、DCM(4x1分)、エーテル(3x1分)で洗浄してから、真空下で乾燥させた。
実施例3で得られたペプチド樹脂上にR1アセチル基を導入するための手順
実施例3で得られたペプチド樹脂1mモルを、25当量のDIEAの存在下で、溶媒として5mLのDMFを用いて、25当量の無水酢酸で処理した。これを30分反応させた後、ペプチド樹脂をDMF(5x1分)、DCM(4x1分)、ジエチルエーテル(4x1分)で洗浄し、真空乾燥させた。
実施例3、4及び5で得られたペプチド樹脂の切断手順
実施例3、4及び5で得られた乾燥ペプチド樹脂200mgを、室温にて撹拌しながら2時間、5mLのTFA:TIS:H2O(90:5:5)で処理した。濾液を50mLの冷ジエチルエーテル上に収集して、多孔性ポリエチレンディスクを取り付けたポリプロピレンシリンジを通して濾過した後、50mLのジエチルエーテルで5回洗浄した。最終析出物を真空下で乾燥させた。
ポリマー支持体の切断手順及びR2置換アミンによる官能化:Fmoc−Wn−Xm−AA1−AA2−AA3−AA4−AA5−AA6−Yp−Zq−NH−(CH2)15−CH3(AA1は、−L−His−又は−L−Ser−であり;AA2は、−L−Ile−又は−L−Val−であり;AA3は、−L−Tyr−又は−L−Val−であり;AA4は、−L−Val−であり;AA5は、−L−Ala−、−L−Arg−又は−Gly−であり;AA6は、−L−Thr−又は−L−Val−であり;n、m、p及びqは、0である)の取得
ヒトPGC−1αプロモーター活性の調節
ヒトPGC−1αのプロモーターの調節能力を、ヒトPGC−1αプロモーターの調節下でルシフェラーゼ遺伝子でトランスフェクトした肝細胞Hep G2癌細胞系において、本発明のペプチドにより評価した。20,000細胞/25cm2プレート)の密度で細胞を接種し、RPMI−1640完全培地で24時間インキュベートした後、本発明のペプチドを0.5mg/mLで添加し、さらに24時間インキュベートした。RPMI−1640完全培地(担体)を負の対照として用いた。プロモーターの活性の測定は、製造業者の指示に従って、Steady−Glo(登録商標)Luciferase Assay System(PROMEGA)キットを用いて実施した。ルミノメーターにより630nmでルミネセンス値を読み取り、プロモーターの活性を決定し、これを負の対照の値に対して標準化した。
PGC−1α遺伝子の転写に対するペプチドAc−L−Ser−L−Ile−L−Tyr−L−Val−L−Ala−L−Thr−NH2及びAc−L−Ser−L−Val−L−Val−L−Val−L−Arg−L−Thr−NH2の作用
遺伝子PGC−1αの発現レベルを定量的リアルタイムPCRによって測定した。ヒト皮下前駆脂肪細胞系を、100μLの容量中100,000細胞/ウェルの密度で、PGM(商標)−2培地において24時間インキュベートした。0.1mg/mLで10日間、ペプチドAc−L−Ser−L−Ile−L−Tyr−L−Val−L−Ala−L−Thr−NH2及びAc−L−Ser−L−Val−L−Val−L−Val−L−Arg−L−Thr−NH2の存在下で、培地をPDM−2に交換することにより、分化を誘導し、その後、細胞を溶解して、RNAを抽出した。PCRは定量的リアルタイムで、Taqman(登録商標)Gene Expression Cells−to−CT(Applied Biosystems)キットを、製造業者の指示に従い用いて、また、適切なプローブ(PGC−1α遺伝子には、Taqman(登録商標)Hs01016719_m1プローブを、また、真核生物リボソームサブユニット18Sには、Taqman(登録商標)Hs99999901_s1プローブ)と一緒に実施し、得られた値を、最大分化対照(PDM−2培地、最大量のPGC−1αmRNA)及び最小分化(PGM(商標)−2培地、最小量のPGC−1αmRNA)に対して標準化した。
脂質蓄積の調節
ヒト皮下前駆脂肪細胞中の脂質の蓄積レベルをAdipoRed(商標)(Lonza)試薬を用いて定量した。ウェル当たり100,000細胞をPGM(商標)−2培地において最終容量100μLで培養した。24時間後、0.1mg/mLの異なるペプチドの存在下で、培地をPDM−2に交換することによって、前駆脂肪細胞から成熟脂肪細への細胞分化を誘導した。分化用培地中のペプチドによる処理から10日後に、製造業者の指示に従ってAdipoRed(商標)試薬を用い、AdipoRed(商標)試薬を添加した後、サンプルの蛍光(励起波長485nm及び蛍光波長535nm)を測定して、細胞内脂質の量を評価した。蛍光値を基底蛍光に対して補正して、最大分化対照(PDM−2培地、最大の脂質蓄積)及び最小分化(PGM(商標)−2培地、最小の脂質蓄積)に対して標準化した。
Ac−L−Ser−L−Val−L−Val−L−Val−L−Gly−L−Val−NH2を含む油中水型(w/o)マイクロエマルジョンの調製
好適な容器中で、カプリル/カプリン酸トリグリセリド[INCl:カプリル/カプリン酸トリグリセリド]、オレイン酸[INCl:オレイン酸]、Edenor LS2M GS[INCl:ステアリン酸、パルミチン酸]及びセラミド[INCl:セラミド3]を混合して(A1相成分)、80〜85℃に加熱した。
Ac−L−Ser−L−Val−L−Val−L−Val−L−Arg−L−Thr−NH2を含むナノ構造脂質担体のコアセルベートの調製
好適な容器中に、以下のものを記載の順に添加した:水[INCl:水(アクア)]、ヒドロキシプロピルデンプンリン酸[INCl:ヒドロキシプロピルデンプンリン酸]、スクレロチウムガム[INCl:スクレロチウムガム]、ヒアルロン酸ナトリウム[INCl:ヒアルロン酸ナトリウム]、プロパンジオール[INCl:プロパンジオール]、フェノキシエタノール[INCl:フェノキシエタノール](A相成分)。A相からの成分の混合物を65℃で加熱した。
Ac−L−Ser−L−Ile−L−Tyr−L−Val−L−Ala−L−Thr−NH2を含むマイクロエマルジョンのナノカプセルの調製
好適な容器中に、水[INCl:水(アクア)]、ヒドロキシプロピルデンプンリン酸[INCl:ヒドロキシプロピルデンプンリン酸]、スクレロチウムガム[INCl:スクレロチウムガム]、ヒアルロン酸ナトリウム[INCl:ヒアルロン酸ナトリウム]、プロパンジオール[INCl:プロパンジオール]、フェノキシエタノール[INCl:フェノキシエタノール]を添加した(A相成分)。A相成分の混合物を65℃に加熱した。
Ac−L−Ser−L−Val−L−Val−L−Val−L−Arg−L−Thr−NH2を含むフェイシャル美容組成物の調製
好適な容器中に、水[INCl:水(アクア)]、ペンチレングリコール[INCl:ペンチレングリコール]、及びベンジルアルコール[INCl:ベンジルアルコール]を一緒に混合した(A相成分)。カルボマー[INCl:カルボマー](A1相成分)及びセチルリン酸カリウム[INCl:セチルリン酸カリウム]をA相に定速で撹拌しながら添加して(A2相成分)、完全に溶解させた。混合物を65〜70℃に加熱した。
実施例13のマイクロエマルジョンのナノカプセルを含む全身用美容組成物の調製
好適な容器中に、水[INCl:水(アクア)]、ベタイン[INCl:ベタイン]、グリセリン[INCl:グリセリン]、ペンチレングリコール[INCl:ペンチレングリコール]及びベンジルアルコール[INCl:ベンジルアルコール]を溶解するまで一緒に混合した(A相成分)。カルボマー[INCl:カルボマー](A1相成分)及びセチルリン酸カリウムを定速で撹拌しながら添加した(A2相成分)後、混合物を65〜70℃に加熱した。
Ac−L−Ser−L−Val−L−Val−L−Val−L−Arg−L−Thr−NH2を含む全身用美容組成物の調製
好適な容器中に、水[INCl:水(アクア)]、ベタイン[INCl:ベタイン]、グリセリン[INCl:グリセリン]、ペンチレングリコール[INCl:ペンチレングリコール]及びベンジルアルコール[INCl:ベンジルアルコール]を溶解するまで一緒に混合した(A相成分)。カルボマー[INCl:カルボマー](A1相成分)及びセチルリン酸カリウムを定速で撹拌しながら添加した(A2相成分)後、混合物を65〜70℃に加熱した。
蜂巣炎の軽減に対する実施例15の組成物の作用
健康な皮膚を有し、ピンチテストによるレベルI〜IIIの蜂巣炎に罹患している25〜45歳の20人の白人のボランティアに、実施例15の組成物を一方の腿に、プラセボ組成物(ペプチドを含まない実施例15と同じ組成物)を他方の腿に、21日にわたって1日2回塗った。真皮−皮下組織接合線の長さを、試験の開始時及び終了時(21日)に、Ultrasound Scanner Dermascan C(登録商標)(Cortex Technology,Denmark)を用いて計器により評価した。真皮−皮下組織接合線の長さの測定値は、蜂巣炎の形成及び皮膚のでこぼこに関連している[Quatresooz P et al.,“Cellulite histopathology and related mechanobiology”,(2006),Int.J.Cosm.Sci.,28,207−210]。真皮−皮下組織接合線の長さが短くなれば、より柔軟かつ滑らかな皮膚がもたらされ、従って、蜂巣炎は目立たなくなる。
乳房の量に対する実施例16の組成物の作用
健康な皮膚を有し、ブラジャーのサイズが36C〜40Eの25〜40歳の22人の白人のボランティアに、実施例16の組成物を一方の乳房に、プラセボ組成物(ペプチドを含まない実施例16と同じ組成物)を他方の乳房に、56日にわたって1日2回塗った。試験の開始時、組成物の塗布から14日及び28日後、並びに試験の終了時(56日)に、乳房の量をmm3で計算することができるFast Optical In VivoTopometry Techniqueを用いて乳房の量を計器により評価した。乳房の量は、初め100,000mm3の任意の値に標準化し、最初の量に対して、乳房の量の変化を様々な処置時間で測定した。
Claims (17)
- 一般式(I):
R1−AA1−AA2−AA3−AA4−AA5−AA6−R2(I)
のペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩において、
AA1は、−His−及び−Ser−からなる群から選択され;
AA2は、−Ile−及び−Val−からなる群から選択され;
AA3は、−Tyr−及び−Val−からなる群から選択され;
AA4は、−Val−であり;
AA5は、−Ala−、−Arg−及び−Gly−からなる群から選択され;
AA6は、−Thr−及び−Val−からなる群から選択され;
R1は、H及びR5−CO−からなる群から選択され、ここで、R5は、H及びC1−C24アルキルからなる群から選択され;
R2は、−NR3R4及び−OR3からなる群から選択され、ここで、R3及びR4は、独立して、H及びC1−C24アルキルからなる群から選択され;
ここで、R1及びR2は、αアミノ酸ではないことを特徴とする、一般式(I)のペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩。 - 請求項1に記載の一般式(I)のペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩において、R1が、H、アセチル、ラウロイル、ミリストイル又はパルミトイルからなる群から選択され、AA1は、−L−Ser−、AA2は、−L−Ile−、AA3は、−L−Tyr−、AA4は、−L−Val−、AA5は、−L−Ala−、AA6は、−L−Thr−であり、かつ、R2は、−NR3R4又は−OR3であり、ここで、R3及びR4は、独立して、H、メチル、エチル、ヘキシル、ドデシル及びヘキサデシルから選択されることを特徴とする、一般式(I)のペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩。
- 請求項1に記載の一般式(I)のペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩において、R1が、H、アセチル、ラウロイル、ミリストイル又はパルミトイルからなる群から選択され、AA1は、−L−Ser−、AA2は、−L−Val−、AA3は、−L−Tyr−、AA4は、−L−Val−、AA5は、−L−Ala−、AA6は、−L−Thr−であり、かつ、R2は、−NR3R4又は−OR3であり、ここで、R3及びR4は、独立して、H、メチル、エチル、ヘキシル、ドデシル及びヘキサデシルから選択されることを特徴とする、一般式(I)のペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩。
- 請求項1に記載の一般式(I)のペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩において、R1が、H、アセチル、ラウロイル、ミリストイル又はパルミトイルからなる群から選択され、AA1は、−L−Ser−、AA2は、−L−Ile−、AA3は、−L−Val−、AA4は、−L−Val−、AA5は、−L−Gly−、AA6は、−L−Thr−であり、かつ、R2は、−NR3R4又は−OR3であり、ここで、R3及びR4は、独立して、H、メチル、エチル、ヘキシル、ドデシル及びヘキサデシルから選択されることを特徴とする、一般式(I)のペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩。
- 請求項1に記載の一般式(I)のペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩において、R1が、H、アセチル、ラウロイル、ミリストイル及びパルミトイルからなる群から選択され、AA1は、−L−Ser−、AA2は、−L−Val−、AA3は、−L−Val−、AA4は、−L−Val−、AA5は、−L−Arg−、AA6は、−L−Thr−であり、かつ、R2は、−NR3R4又は−OR3であり、ここで、R3及びR4は、独立して、H、メチル、エチル、ヘキシル、ドデシル又はヘキサデシルから選択されることを特徴とする、一般式(I)のペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩。
- 請求項1に記載の一般式(I)のペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩において、R1が、H、アセチル、ラウロイル、ミリストイル及びパルミトイルからなる群から選択され、AA1は、−L−His−、AA2は、−L−Ile−、AA3は、−L−Val−、AA4は、−L−Val−、AA5は、−L−Gly−、AA6は、−L−Thr−であり、かつ、R2は、−NR3R4又は−OR3であり、ここで、R3及びR4は、独立して、H、メチル、エチル、ヘキシル、ドデシル及びヘキサデシルから選択されることを特徴とする、一般式(I)のペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩。
- 請求項1〜6のいずれか一項に記載の一般式(I)のペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩において、PGC−1α調節での使用を目的とすることを特徴とする、一般式(I)のペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩。
- 請求項1〜6のいずれか一項に記載の一般式(I)のペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩において、代謝疾患及び/又は障害、脂質代謝に関する疾患、糖新生の変化、肥満、2型糖尿病、蜂巣炎、女性化乳房、偽性女性化乳房、脂肪萎縮症、半月形脂肪萎縮症、脂肪異栄養、老化、光老化、皮膚損傷、外傷の上皮再形成、皮膚の脱水、乾燥症、角化障害、硬結、皮膚肥厚、乾癬、扁平苔癬、狼瘡に関連する皮膚の病変、皮膚炎、アトピー性皮膚炎、脂漏性皮膚炎、老人性皮膚炎、フケ、新生児頭部皮膚炎、脂漏症、挫瘡の高脂漏症、日光性皮膚炎 脂漏性角化症、老人性角化症、日光性角化症、光誘導性角化症、毛包性角化症、尋常性挫瘡、母斑、ケロイド、線維芽細胞の機能の変化、結節性筋膜炎、強皮症、デュピュイラン拘縮、線維性瘢痕形成、皮脂腺の障害、酒さ性挫瘡、多形性挫瘡、面皰、多形性、酒さ、嚢胞性挫瘡、集簇性挫瘡、老人性挫瘡、魚鱗癬、ダリエー病、掌蹠角化症、白板症、粘膜苔癬、皮膚苔癬、皮膚乾癬、粘膜乾癬、爪乾癬、乾癬性リウマチ、湿疹、尋常性疣贅、扁平疣贅、疣贅状表皮発育異常症、口部乳頭腫、紅斑性狼瘡、水疱性疾患、水疱性類天疱瘡、強皮症、日光性角化症、色素異常症、白斑、円形脱毛症、アルツハイマー病、パーキンソン病、ハンチントン病、ピック病、クーフス病、レビー小体認知症、神経原線維濃縮体、ローゼンタール線維、マロリーヒアリン、老人性痴呆症、重症筋無力症、ジル・ドゥ・ラ・トゥレット症候群、多発性硬化症、筋委縮性側索硬化症、進行性核上性麻痺、てんかん、クロイツフェルト・ヤコブ病、聾・ジストニー症候群、リー病、レーベル遺伝性視神経症、パーキンソン症候群、ジストニア、運動ニューロン疾患、ニューロパシー症候群、運動失調及び網膜色素変性症、母系遺伝性リー病、フリードライヒ運動失調症、遺伝性痙性対麻痺、モーア・トラネジャーグ症候群、ウィルソン病、散発性アルツハイマー病、散発性筋委縮性側索硬化症、散発性パーキンソン病、自律機能の変化、高血圧、睡眠障害、神経精神疾患、うつ病、統合失調症、統合失調感情障害、コルサコフ精神病、躁病、不安障害、恐怖症、学習又は記憶障害、健忘症若しくは加齢による記憶喪失、注意欠陥障害、気分変調性障害、大うつ病性障害、強迫性障害、精神作用物質の使用による障害、パニック障害、双極性障害、片頭痛、多動性障害及び運動障害からなる群から選択される病態、障害若しくは疾患の治療及び/又はケアでの使用を目的とすることを特徴とする、一般式(I)のペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩。
- 請求項1〜6のいずれか一項に記載の一般式(I)のペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩において、皮膚の治療及び/又はケアでの使用を目的とすることを特徴とする、一般式(I)のペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩。
- 請求項7又は9に記載の一般式(I)のペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩において、前記脂肪組織の量を増加若しくは減少させる、又は前記脂肪組織のトリグリセリド含有量を増加若しくは減少させる、又は蜂巣炎の出現を軽減、予防若しくは遅延させることを特徴とする、一般式(I)のペプチド、その立体異性体、その立体異性体の混合物及び/又は美容的若しくは薬学的に許容されるその塩。
- 請求項9に記載の一般式(I)のペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩において、前記治療及び/又はケアが、老化及び/又は光老化の徴候を軽減、遅延及び/又は予防することを特徴とする、一般式(I)のペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩。
- 請求項7に記載の一般式(I)のペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩において、前記皮膚の温度を高めることを特徴とする、一般式(I)のペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩。
- 請求項1〜6のいずれか1項に記載の一般式(I)の少なくとも1つのペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩を美容的又は薬学的に有効な量で含むと共に、少なくとも1種の美容的若しくは薬学的に許容可能な賦形剤又は補助剤を含有することを特徴とする、美容又は医薬組成物。
- 請求項13に記載の組成物において、一般式(I)の前記ペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩が、リポソーム、混合リポソーム、オレオソーム、ニオソーム、エトソーム、ミリカプセル、マイクロカプセル、ナノカプセル、ナノ構造脂質担体、スポンジ、シクロデキストリン、小胞、ミセル、界面活性剤の混合ミセル、界面活性剤−リン脂質混合ミセル、ミリスフェア、マイクロスフェア、ナノスフェア、リポスフェア、マイクロエマルジョン、ナノエマルジョン、ミニ粒子、ミリ粒子、マイクロ粒子、ナノ粒子及び固体脂質ナノ粒子からなる群から選択される美容若しくは医薬用送達系又は徐放系に組み込まれるか、あるいは、タルク、ベントナイト、シリカ、デンプン及びマルトデキストリンからなる群から選択される、美容的若しくは薬学的に許容される固体有機ポリマー又は固体無機支持体上に吸着されていることを特徴とする、組成物。
- 請求項13又は14に記載の組成物において、クリーム、多相エマルジョン、無水組成物、水性分散液、オイル、ミルク、バルサム、フォーム、ローション、ジェル、クリームジェル、水性アルコール溶液、水性グリコール溶液、ヒドロゲル、リニメント、血清、石鹸、シャンプー、コンディショナー、しょう液、軟膏、ムース、ポマード、粉末、棒状製剤、ペンシル型製剤、スプレー、エアロゾル、ゼラチンカプセル、ソフトカプセル、ハードカプセル、錠剤、糖衣錠、顆粒、チューインガム、溶液、懸濁液、エマルジョン、シロップ、エレキシル、多糖フィルム、ゼリー及びゼラチンからなる群から選択される製剤として提供されるか、あるいは、目元コンシーラー、メイクアップファンデーション、メイク落としローション、メイク落としミルク、アイシャドウ、口紅、リップグロス、リッププロテクター、及びパウダーからなる群から選択される製品に組み込まれていることを特徴とする、組成物。
- 請求項13又は14に記載の組成物において、一般式(I)の前記ペプチド、その立体異性体、その立体異性体の混合物及び/又はその美容的若しくは薬学的に許容可能な塩が、布、不織布又は医療装置に組み込まれていることを特徴とする、組成物。
- 請求項13〜16のいずれか一項に記載の組成物において、さらに、他のPGC−1α調節剤、他のPPARγ調節剤、脂肪細胞のトリグリセリド含有量を増加又は減少させる他の薬剤、脂肪細胞分化を刺激又は遅延させる薬剤、脂肪分解剤又は脂肪分解を刺激する薬剤、抗セルライト剤、脂肪生成剤、脂肪細胞の増殖を刺激する薬剤、アセチルコリン受容体凝集の阻害剤、筋収縮の阻害剤、抗コリン作動薬、エラスターゼ阻害剤、マトリックスメタロプロテアーゼ阻害剤、メラニン合成の刺激若しくは阻害剤、美白若しくは脱色剤、着色促進剤、セルフタンニング剤、老化防止剤、NO−シンターゼ阻害剤、5α−レダクターゼ阻害剤、リシル−及び/若しくはプロリルヒドロキシラーゼ阻害剤、酸化防止剤、遊離ラジカル捕捉剤及び/若しくは大気汚染からの保護剤、反応性カルボニル種捕捉剤、抗糖化剤、抗ヒスタミン剤、抗ウイルス剤、抗寄生虫剤、乳化剤、皮膚軟化剤、有機溶媒、液体噴霧剤、スキンコンディショナー、湿潤剤、水分を保持する物質、αヒドロキシ酸、βヒドロキシ酸、保湿剤、表皮加水分解酵素、ビタミン、アミノ酸、タンパク質、顔料若しくは着色剤、色素、生体ポリマー、ゲル化ポリマー、増粘剤、界面活性剤、軟化剤、乳化剤、結合剤、保存料、シワ防止剤、眼の下の腫れを軽減若しくは治療することができる薬剤、剥離剤、落屑剤、角質溶解剤、抗菌剤、抗真菌剤、静真菌剤、殺菌剤、静菌剤、真皮若しくは表皮の高分子合成を刺激する薬剤及び/又はそれらの分解を阻害若しくは予防することができる薬剤、コラーゲン合成刺激剤、エラスチン合成刺激剤、デコリン合成刺激剤、ラミニン合成刺激剤、デフェンシン合成刺激剤、シャペロン合成刺激剤、cAMP合成刺激剤、熱ショックタンパク質、HSP70合成刺激剤、熱ショックタンパク質合成刺激剤、アクアポリン合成刺激剤、ヒアルロン酸合成刺激剤、フィブロネクチン合成刺激剤、サーチュイン合成刺激剤、脂質及び角質層成分、セラミド、脂肪酸、の合成刺激剤、コラーゲン分解の阻害剤、エラスチン分解の阻害剤、セリンプロテアーゼの阻害剤、線維芽細胞増殖の刺激剤、角化細胞増殖の刺激剤、メラノサイト増殖の刺激剤、角化細胞分化の刺激剤、アセチルコリンエステラーゼの阻害剤、皮膚弛緩剤、グリコサミノグリカン合成刺激剤、抗過角化症薬、面皰分解剤、抗乾癬薬、DNA修復剤、DNA保護剤、安定化剤、抗掻痒薬、敏感肌の治療及び/又はケアのための薬剤、固化剤、再緻密化剤、再構築剤、抗ストレッチマーク剤、結合剤、皮脂産生の調節剤、抗発汗剤、治癒刺激剤、治癒共補助剤、上皮再形成の刺激剤、上皮再形成の共補助剤、サイトカイン成長因子、鎮静剤、抗炎症薬、麻酔薬、毛細血管循環及び/若しくは微小循環に作用する薬剤、血管新生の刺激剤、血管透過性の阻害剤、ベノトニック剤、細胞代謝に作用する薬剤、真皮−表皮接合を改善する薬剤、発毛誘発剤、発毛阻害若しくは抑制剤、香料、キレート剤、植物エキス、精油、海産物エキス、生物発酵プロセスから得られる薬剤、無機塩、細胞エキス、日焼け止め並びに紫外線A及び/又はBに対して作用する有機若しくは無機光保護剤、またはこれらの混合物からなる群から選択される少なくとも1種の補助剤を美容的又は薬学的に有効な量で含むことを特徴とする、組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161467648P | 2011-03-25 | 2011-03-25 | |
ES201130439 | 2011-03-25 | ||
ES201130439A ES2397889B1 (es) | 2011-03-25 | 2011-03-25 | PÉPTIDOS MODULADORES DE PGC-1Alfa. |
US61/467,648 | 2011-03-25 | ||
PCT/EP2012/055259 WO2012130775A1 (en) | 2011-03-25 | 2012-03-23 | Pgc-1alpha-modulating peptides |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018132988A Division JP2018193381A (ja) | 2011-03-25 | 2018-07-13 | PGC−1αを調節するペプチド |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014510091A JP2014510091A (ja) | 2014-04-24 |
JP6431367B2 true JP6431367B2 (ja) | 2018-11-28 |
Family
ID=46929508
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014500420A Active JP6431367B2 (ja) | 2011-03-25 | 2012-03-23 | PGC−1αを調節するペプチド |
JP2018132988A Withdrawn JP2018193381A (ja) | 2011-03-25 | 2018-07-13 | PGC−1αを調節するペプチド |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018132988A Withdrawn JP2018193381A (ja) | 2011-03-25 | 2018-07-13 | PGC−1αを調節するペプチド |
Country Status (9)
Country | Link |
---|---|
US (1) | US9266921B2 (ja) |
EP (1) | EP2651428B1 (ja) |
JP (2) | JP6431367B2 (ja) |
KR (1) | KR101988676B1 (ja) |
CN (1) | CN103379911B (ja) |
AU (1) | AU2012234370B2 (ja) |
BR (1) | BR112013020002B1 (ja) |
ES (2) | ES2397889B1 (ja) |
WO (1) | WO2012130775A1 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE034308T2 (en) | 2013-03-21 | 2018-02-28 | Sanofi Aventis Deutschland | Preparation of hydantoin-containing peptide products |
CA2907521C (en) | 2013-03-21 | 2021-04-13 | Sanofi-Aventis Deutschland Gmbh | Synthesis of cyclic imide containing peptide products |
JP6712273B2 (ja) * | 2015-01-07 | 2020-06-17 | アボカ エッセ.ピ.ア.ソシエタ アグリコラ | 肥満主体のためのリンパ排出用組成物 |
CN104523449A (zh) * | 2015-01-08 | 2015-04-22 | 上海圣婕化妆品有限公司 | 一种抗衰老多胜肽复合物及其应用 |
CN104622779A (zh) * | 2015-01-08 | 2015-05-20 | 上海圣婕化妆品有限公司 | 一种多胜肽抗衰老修复面膜精华液及其制备方法 |
EP3411012A4 (en) | 2016-02-04 | 2019-08-28 | Alastin Skincare, Inc. | COMPOSITIONS AND METHODS FOR INVASIVE AND NON-INVASIVE SKIN CARE PROCEDURES |
US10493020B2 (en) | 2016-04-14 | 2019-12-03 | The Procter & Gamble Company | Method of improving the appearance of periorbital dyschromia |
CN106943589B (zh) * | 2017-05-19 | 2020-07-10 | 天津医科大学总医院 | PGC-1α在制备治疗血管性痴呆药物中的用途 |
AU2018309058B2 (en) | 2017-08-03 | 2023-02-16 | ALASTIN Skincare, Inc. | Compositions and methods for ameliorating skin laxity and body contour |
CN107325157B (zh) * | 2017-08-07 | 2020-06-26 | 温州千瑞生物科技有限公司 | 调节皮脂分泌的肽以及包含其的化妆品 |
WO2020028694A1 (en) | 2018-08-02 | 2020-02-06 | ALASTIN Skincare, Inc. | Liposomal compositions and methods of use |
US20210401728A1 (en) * | 2018-10-26 | 2021-12-30 | Ivan GALANIN | Topical Compositions and Methods to Promote Optimal Dermal White Adipose Tissue Composition in Vivo |
TR201901740A2 (tr) * | 2019-02-05 | 2019-03-21 | Dr Seyda Atabay Saglik Ve Kozmetik Ueruenleri A S | Gözalti morluklarinin tedavi̇si̇ i̇çi̇n jel bazli formülasyon |
CN109750012B (zh) * | 2019-03-27 | 2021-10-15 | 云南师范大学 | 一种脂肪酶突变体及其应用 |
CN112043627B (zh) * | 2020-09-04 | 2023-02-03 | 高颜苑科技(深圳)有限责任公司 | 一种毛发生长的氨基酸溶液组合物及其制备方法 |
JP2024508747A (ja) * | 2021-02-17 | 2024-02-28 | アラスティン・スキンケア・インコーポレイテッド | 脱毛症に関する組成物及び方法 |
CN115670965B (zh) * | 2021-05-17 | 2024-04-19 | 杭州朝与暮品牌管理有限公司 | 一种有效抑制IL-8、TNF-α和IL-6的皮肤抗炎组合物 |
WO2023099775A1 (en) | 2021-12-03 | 2023-06-08 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | Lipolytic peptides |
CN113980097B (zh) * | 2021-12-29 | 2022-03-29 | 浙江湃肽生物有限公司南京分公司 | 棕榈酰三肽-5的纯化方法 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5348943A (en) | 1985-02-08 | 1994-09-20 | Procyte Corporation | Cosmetic and skin treatment compositions |
US5594015A (en) | 1994-06-22 | 1997-01-14 | Regents Of The University Of California | Thiazolidine derivatives for the treatment of psoriasis |
US6426411B1 (en) * | 1997-05-30 | 2002-07-30 | Dana-Farber Cancer Institute | PGC-1, a novel brown fat pparγ coactivator |
FR2773075B1 (fr) | 1997-12-31 | 2000-05-05 | Cird Galderma | Utilisation d'activateurs de ppar-gamma en dermatologie |
US20020049176A1 (en) | 1999-11-10 | 2002-04-25 | Anderson Christen M. | Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery |
US20030044475A1 (en) | 2000-03-24 | 2003-03-06 | Van De Wiel Andriaan Emanuel Hendricus Anna Maria | Cosmetic use of hop and ornithine |
WO2002032938A2 (en) * | 2000-10-17 | 2002-04-25 | Bayer Aktiengesellschaft | Regulation of human pgc-1-like protein |
WO2002038150A1 (de) | 2000-11-09 | 2002-05-16 | Phenion Gmbh & Co. Kg | Aktivatoren von peroxisom-proliferator-aktivierten rezeptoren alpha, beta als arzneimittel zur behandlung von immunologisch bedingten hautstörungen |
GB2369572A (en) | 2000-11-29 | 2002-06-05 | Raft Trustees Ltd | Wound treatment composition comprising insulin |
EP1234572B1 (de) | 2001-02-26 | 2013-10-30 | Mibelle AG Cosmetics | Isoflavon-Aglykone enhaltende Hautbehandlungsmittel |
JP2004532230A (ja) | 2001-04-30 | 2004-10-21 | アラクノーバ・セラピューティックス・リミテッド | Ppar−ガンマアクチベーターを使用する瘢痕化および関連状態の処置 |
AU2003219788A1 (en) | 2002-02-13 | 2003-09-04 | Dana-Farber Cancer Institute, Inc. | METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1Alpha- |
US8513407B2 (en) | 2002-06-18 | 2013-08-20 | Glycores 2000 S.R.L. | Process for the preparation of N-acyl-(epi)K5-amine-O-sulfate-derivatives and products thus obtained |
FR2874379B1 (fr) | 2004-08-17 | 2006-10-27 | Galderma Res & Dev | Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
US7947652B2 (en) | 2004-09-03 | 2011-05-24 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating PGC-1α to treat huntington's disease |
US7410658B2 (en) | 2004-12-22 | 2008-08-12 | Avon Products, Inc. | Use of Alisma orientale in cosmetics and compositions thereof |
US7618662B2 (en) | 2004-12-22 | 2009-11-17 | Avon Products, Inc | Use of natural plant extracts in cosmetic compositions |
BRPI0500959A (pt) | 2005-03-23 | 2006-11-21 | Unicamp | uso farmacológico de inibidor da expressão da proteìna coativador 1 alfa do receptor ativado por proliferador do peroxisoma (pgc-1(alfa)) para o tratamento de diabetes mellitus, resistência à insulina e sìndrome metabólica, seu composto e sua composição farmacêuticos |
CN100368562C (zh) * | 2005-10-18 | 2008-02-13 | 卫生部北京医院 | 一种鉴定pgc-1基因启动子-1436位snp分子标记的引物、方法及试剂盒 |
JP2007217368A (ja) * | 2006-02-17 | 2007-08-30 | Japan Health Science Foundation | PGC−1α発現促進剤及びPGC−1α発現抑制剤、並びにそれらの使用方法 |
FR2904549B1 (fr) | 2006-08-03 | 2012-12-14 | Sederma Sa | Composition comprenant de la sarsasapogenine |
ES2316312B1 (es) | 2008-06-20 | 2010-02-08 | Ignacio Umbert Millet | Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas. |
FR2941151B1 (fr) | 2009-01-22 | 2012-05-11 | Caster | Extrait de lentinus pour son action sur la cellulite et les amas graisseux. |
DE102009033740A1 (de) | 2009-07-17 | 2011-02-03 | Dr. Scheller Cosmetics Ag | Kosmetische Zusammensetzung, insbesondere zur Anwendung bei Cellulite |
US9132178B2 (en) * | 2009-08-26 | 2015-09-15 | Immunotope, Inc. | Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of cancer |
WO2010089421A2 (en) | 2010-05-25 | 2010-08-12 | Symrise Gmbh & Co. Kg | Menthyl carbamate compounds as active anti-cellulite ingredients |
-
2011
- 2011-03-25 ES ES201130439A patent/ES2397889B1/es not_active Expired - Fee Related
-
2012
- 2012-03-23 AU AU2012234370A patent/AU2012234370B2/en active Active
- 2012-03-23 CN CN201280005815.8A patent/CN103379911B/zh active Active
- 2012-03-23 EP EP12710106.1A patent/EP2651428B1/en active Active
- 2012-03-23 KR KR1020137027976A patent/KR101988676B1/ko active IP Right Grant
- 2012-03-23 JP JP2014500420A patent/JP6431367B2/ja active Active
- 2012-03-23 WO PCT/EP2012/055259 patent/WO2012130775A1/en active Application Filing
- 2012-03-23 ES ES12710106.1T patent/ES2600852T3/es active Active
- 2012-03-23 BR BR112013020002-2A patent/BR112013020002B1/pt active IP Right Grant
- 2012-03-23 US US14/006,981 patent/US9266921B2/en active Active
-
2018
- 2018-07-13 JP JP2018132988A patent/JP2018193381A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2018193381A (ja) | 2018-12-06 |
BR112013020002B1 (pt) | 2022-10-04 |
AU2012234370A1 (en) | 2013-07-18 |
ES2397889A1 (es) | 2013-03-12 |
BR112013020002A2 (pt) | 2017-09-19 |
US20140086981A1 (en) | 2014-03-27 |
EP2651428B1 (en) | 2016-08-03 |
JP2014510091A (ja) | 2014-04-24 |
EP2651428A1 (en) | 2013-10-23 |
CN103379911B (zh) | 2016-05-25 |
CN103379911A (zh) | 2013-10-30 |
WO2012130775A1 (en) | 2012-10-04 |
US9266921B2 (en) | 2016-02-23 |
ES2397889B1 (es) | 2014-02-07 |
ES2600852T3 (es) | 2017-02-13 |
KR20140041467A (ko) | 2014-04-04 |
KR101988676B1 (ko) | 2019-06-12 |
AU2012234370B2 (en) | 2017-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6431367B2 (ja) | PGC−1αを調節するペプチド | |
JP6522509B2 (ja) | 皮膚、毛髪および/または粘膜の処置および/またはケアにおいて有用な化合物ならびにそれらの化粧品組成物または医薬組成物 | |
JP7010823B2 (ja) | 皮膚、毛髪、爪および/または粘膜の処置および/またはケアにおいて有用な化合物 | |
TWI631141B (zh) | 用來抑制經活化受體之胜肽及其於化妝或醫藥組成物中之用途 | |
CN104254339B (zh) | 用于治疗和/或护理皮肤和/或粘膜的化合物和它们在化妆品组合物或药物组合物中的用途 | |
JP6075650B2 (ja) | 皮膚及び/又は粘膜の治療及び/又はケアに有用なペプチド並びに化粧品若しくは医薬組成物におけるそれらの使用 | |
KR20190067218A (ko) | 피부, 헤어, 네일 및/또는 점막의 치료 및/또는 케어를 위해 유용한 화합물 | |
JP2020525529A (ja) | 皮膚、毛髪、爪および/または粘膜の処置および/またはケアに有用な化合物 | |
JP7526159B2 (ja) | 皮膚、毛髪、爪および/または粘膜の処置および/またはケアに有用な化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150319 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160223 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160520 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160719 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160823 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170519 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180613 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180713 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181102 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6431367 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |